Multi-parametric metabolic assessment of cells under stress conditions by Waters, Alicia H. C.
Title Multi-parametric metabolic assessment of cells under stress conditions
Author(s) Waters, Alicia H. C.
Publication date 2015
Original citation Waters, A. H. C. 2015. Multi-parametric metabolic assessment of cells
under stress conditions. PhD Thesis, University College Cork.
Type of publication Doctoral thesis
Rights © 2015, Alicia H. C. Waters.
http://creativecommons.org/licenses/by-nc-nd/3.0/
Embargo information Please note that Chapter 4 (pp.109-134) is unavailable due to a
restriction requested by the author.
Embargo lift date 2018-11-18T10:13:12Z
Item downloaded
from
http://hdl.handle.net/10468/2075
Downloaded on 2017-02-12T06:00:10Z
 
 
 
 
MULTI-PARAMETRIC METABOLIC ASSESSMENT OF CELLS UNDER 
STRESS CONDITIONS 
 
A THESIS SUBMITTED TO THE NATIONAL UNIVERSITY OF IRELAND, CORK IN 
THE FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY  
BY 
 
 
Alicia Holly Clare Waters M.Sc. 
 
 
 
School Of Biochemistry and Cell Biology 
University College Cork 
Ireland 
January 2015 
 
 
Supervisor: Prof. Dmitri Papkovsky 
Head of Department; Prof. David Sheehan 
 
 
 
 
TABLE OF CONTENTS 
Declaration ................................................................................................................... 1 
Abstract ........................................................................................................................ 2 
List of Abbreviations .................................................................................................... 4 
Thesis Objectives .......................................................................................................... 6 
Chapter 1.  Introduction and Literature Review .......................................................... 7 
1.1 Metabolism of mammalian cells ............................................................................ 8 
1.1.1 Glycolysis and the Krebs cycle ................................................................... 10 
1.1.2 Oxidative Phosphorylation ........................................................................ 12 
1.1.3 Cell Bioenergetics ...................................................................................... 16 
1.2 Regulation of Metabolism ................................................................................ 19 
1.2.1 Metabolic Substrates ................................................................................. 19 
1.2.2 Starvation and Hypoxia .............................................................................. 23 
1.2.3 Metabolic Enzymes .................................................................................... 24 
1.2.4 Calcium and Calcium Transporters ............................................................ 29 
1.3. Cell/Tissue Oxygenation and Hypoxia ............................................................. 34 
1.3.1 HIFs ............................................................................................................ 36 
1.4. Methods of assessment of cell metabolism and bioenergetics ...................... 39 
1.4.1 Traditional methods................................................................................... 40 
1.4.2 New approaches ........................................................................................ 42 
Chapter 2.  Materials and Methods ........................................................................... 49 
2.1  Materials .......................................................................................................... 50 
2.2 Methods ........................................................................................................... 55 
2.2.1 Cell Culture ................................................................................................. 55 
2.2.2 Cell Based Assays ....................................................................................... 58 
2.2.3 Protein Isolation and Western Blot analysis .............................................. 61 
2.2.4 BCA Protein Assay ...................................................................................... 61 
2.2.5 RNA Isolation and Reverse Transcription and q-PCR ................................. 62 
2.2.6 Statistical Analysis ...................................................................................... 62 
Chapter 3.  Application of Cell Energy Budget Platform in Toxicological and 
Metabolic Studies with cell models ........................................................................... 64 
3.1 Abstract ............................................................................................................ 65 
3.2 Introduction ...................................................................................................... 66 
3.2.1 The Cell Energy Budget (CEB) platform ..................................................... 66 
3.2.2 Aims ........................................................................................................... 69 
3.3 Results .............................................................................................................. 70 
3.3.1 Toxicity Testing of Nanoparticle Preparations .......................................... 70 
 
 
 
 
3.3.2 Metabolic Substrates in Cell Bioenergetics ............................................... 75 
3.3.3 Differential contribution of key metabolic substrates and O2 in HIF 
signalling ............................................................................................................. 90 
3.4 Discussion ....................................................................................................... 101 
3.5 Conclusions ..................................................................................................... 108 
Chapter 4. Regulation of Pyruvate Dehydrogenase Complex by Hypoxia, Pyruvate 
and Calcium .............................................................................................................. 109 
4.1 Abstract .......................................................................................................... 110 
4.2 Introduction .................................................................................................... 111 
4.2.1 Regulation of Pyruvate Dehydrogenase Phosphorylation ...................... 111 
4.2.2 Role of hypoxia in mitochondrial Ca2+ turnover ...................................... 113 
4.2.3 Aims ......................................................................................................... 114 
4.3 Results ............................................................................................................ 115 
4.3.1 An increase in PDH E1α phosphorylation under hypoxia may not require 
activation of HIF-1α /PDK1 axis ........................................................................ 115 
4.3.2 Putative roles of PDP1, Ca2+ and pyruvate in PDH E1-α activity ............. 121 
4.3.3 Increased PDP1 mRNA levels in SCO2-/- cells during hypoxia .................. 121 
4.3.4 Mitochondrial pyruvate transport is regulated by ∆Ψm dependent MPC 
activity ............................................................................................................... 121 
4.3.5 Extracellular acidification is dependent on O2 levels in WT and SCO2
-/- 
cells ................................................................................................................... 122 
4.3.6 A decrease in mitochondrial Ca2+ levels in SCO2-/- cells is associated with 
changes in Ca2+ transporters expression .......................................................... 124 
4.4 Discussion ....................................................................................................... 128 
4.5 Conclusions ..................................................................................................... 134 
Overall Conclusions .................................................................................................. 135 
Future Work ............................................................................................................. 137 
References ................................................................................................................ 138 
Appendix .................................................................................................................. 151 
Project Outcomes ..................................................................................................... 181 
Papers ................................................................................................................... 181 
Chebana Marie-Curie Meetings ........................................................................... 181 
International Conferences .................................................................................... 182 
Acknowledgements .................................................................................................. 183 
 
  
  
 
 
1 
 
DECLARATION 
 
This thesis has not been submitted in whole or part to this or any other university 
for any degree, and is, unless otherwise stated, the original work of the author.   
 
_________________      January 2014 
Alicia Waters  
 
 
2 
 
ABSTRACT 
Glycolysis, glutaminolysis, the Krebs cycle and oxidative phosphorylation are the 
main pathways for cell metabolism.  Exposing cells to key metabolic substrates 
(glucose, glutamine and pyruvate 12 combinations in total); we were able to 
investigate the contribution of substrates to effect of stress conditions such as 
uncoupling with FCCP and hypoxia.  A number of parameters were investigated: 
glycolysis, O2 consumption, O2 and ATP levels, and hypoxia inducible factor 
signalling in pheochromocytoma PC12 cells.  Upon uncoupling with FCCP the 
mitochondria were depolarised similarly in all the cases, but a strong increase in 
respiration was only seen in the cells fed on glutamine combined with either 
glucose or pyruvate.  Surprisingly, the response to FCCP did not correlate with ATP 
levels, which rapidly dropped upon uncoupling in the absence of glucose.  Inhibition 
of glutaminolysis resulted in a reversal of the glutamine dependant effect.    
Differential regulation of the respiratory response to FCCP by metabolic 
environment suggests that mitochondrial uncoupling has a potential for substrate-
specific inhibition of cell function, and can be explored for selective cancer 
treatment.  
At reduced O2 availability (4 % and 0 % of atmospheric O2), cell bioenergetics and 
local oxygenation varied drastically depending on the substrate composition.  
Cellular ATP and O2 levels orchestrated hypoxia inducible factor-2α stabilisation.  
These results indicate that both supply and utilisation of key metabolic substrates 
can affect the pattern of hypoxia inducible factor-1/2α accumulation by 
differentially regulating iO2 and ATP levels and Protein kinase B/mitogen-activated 
protein kinase/AMP-activated protein kinase pathways.  Inhibition of key metabolic 
pathways (e.g. glutaminolysis) can modulate hypoxia inducible factor regulatory 
pathways, metabolic responses and survival of cancer cells in hypoxia.  These data 
are of relevance to those studying neuronal and cancer metabolism under hypoxia.   
Hypoxia leads to transcriptional activation, by hypoxia inducible factor, of pyruvate 
dehydrogenase kinase which phosphorylates and inhibits pyruvate dehydrogenase, 
a mitochondrial enzyme that converts pyruvate formed by glycolysis into acetyl-
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CoA, thus feeding the Krebs cycle.  The levels of pyruvate dehydrogenase (total and 
phosphorylated protein) , pyruvate dehydrogenase kinase and hypoxia inducble 
factor-1α was analysed in human colon cancer cells HCT116 wild type  and SCO2-/- 
(deficient in complex IV of the respiratory chain) grown for 1 week under 20.9 % 
and 3 % O2.  Our data on pyruvate dehydrogenase phosphorylation state indicates 
that regulation of the enzyme activity under normoxia and hypoxia can occur in a 
manner independent of the hypoxia inducible factor-1/pyruvate dehydrogenase 
kinase 1 axis, mitochondrial respiration and the demand of the Krebs cycle for 
acetyl-CoA.  This is of particular relevance for those studying possible treatments 
with pyruvate dehydrogenase kinase 1 inhibitors for diabetes, heart disease or 
cancer.   
Collectively these results can be applied to many (patho)physiological diseases such 
as reduced nutrient supply and O2 during ischemia/stroke, hypoglycaemia in 
diabetes mellitus and liver carcinoma patients, and cancer associated changes in 
uncoupling protein expression levels. 
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THESIS OBJECTIVES 
 
Apply metabolic cell energy budget to study: 
1. Toxicity testing of molecular imprinted polymer - nanoparticles. 
2. Cellular response to uncoupling. 
3. Study factors involved in hypoxia inducible factor-α accumulation. 
4. Investigate pyruvate dehydrogenase complex regulation. 
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CHAPTER 1.  INTRODUCTION AND LITERATURE REVIEW 
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 1.1 METABOLISM OF MAMMALIAN CELLS 
  
Mammalian cells have several main metabolic pathways that work together in 
order to maintain the required supply of energy and key metabolites to the cell.  
These are glycolysis, the Krebs cycle, Oxidative Phosphorylation (OxPhos), 
glutaminolysis and the pentose phosphate pathway (Fig. 1.1).  Each pathway has 
spare capacity which can be increased in the event of increased energy demand or 
one of the other pathways not working optimally.  For example in hypoxic 
conditions where there is a reduction in oxygen, OxPhos has a reduced output 
which can be compensated for by an increase in glycolytic activity to maintain 
steady ATP levels.   
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Figure 1.1 Scheme of the main metabolic pathways in mammalian cells (glycolysis, 
glutaminolysis, pentose phosphate pathway, Krebs cycle and oxidative 
Phosphorylation). Glycolysis produces pyruvate (Pyr) which is transported into the 
mitochondria via the mitochondrial Pyr carrier (MPC), converted into acetyl-CoA and 
fed into the Krebs cycle.  The Krebs cycle produces the reducing intermediates 
(NADH) required for oxidative phosphorylation (OxPhos).  Complexes I, III and IV 
pump protons out of the mitochondrial matrix into the inner-mitochondrial space 
creating a gradient which is utilised by Complex V (ATP synthase) to generate ATP.   
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1.1.1 Glycolysis and the Krebs cycle 
Glycolysis, also known as the Embden-Meyerhof pathways, is a series of reactions 
which convert one molecule of glucose into two molecules of pyruvate in the 
cytosol of the cell, generating two ATP molecules per molecule of glucose as well as 
NADH (Fig. 1.1).  There are two phases in glycolysis, a priming phase which utilises 2 
ATP molecules and an energy-yielding phase which generates 4 molecules of ATP 
and 2 molecules of NADH.   Glycolysis is the first stage of three in the complete 
oxidation of glucose and is up-regulated in many different conditions such as O2 
deprivation or certain cancers (Busk et al., 2008, Dang and Semenza, 1999).  
Glycolysis is highly regulated by master metabolic regulators such as AMP-activated 
protein kinase (AMPK), Protein Kinase B (Akt) and hypoxia inducible factors (HIFs) 
(Hardie et al., 2012, Xu et al., 2014, Kim et al., 2006).  Akt has been shown to up-
regulate glycolysis in cancer cells under aerobic conditions (Elstrom et al., 2004).  
This is a prominent effect which is observed in many cancer cells, glycolysis is used 
as the main energy source even when there is sufficient O2 present to allow energy 
production via OxPhos which is a more efficient way to generate ATP (Warburg et 
al., 1927).  This is termed the Warburg effect, which is characterised by increased 
lactate production, glycolytically derived pyruvate is converted into lactate (Xu et 
al., 2014).  This was thought to be due to dysfunctional respiratory chain activity in 
these cells; however it is now known that cancer cells have functional 
mitochondria, observed in glioblastoma cancer stem cells, epithelial ovarian cancer 
stem cells and human breast cancer cells (Obre and Rossignol, 2015, Jose et al., 
2011, Janiszewska et al., 2012, Pastò et al., 2014).  The increased glycolytic activity 
observed in certain cancer cells is thought to fulfil metabolic requirements 
necessary for cell growth.  The Krebs cycle can be maintained through α-
ketoglutarate (α-KG) derived from glutamine through glytaminolysis (Wise et al., 
2008, Fan et al., 2013).  Pyruvate formed from glycolysis enters the mitochondria 
and is converted into acetyl-CoA by pyruvate dehydrogenase (PDH) which is fed 
into the Krebs cycle, also known as the citric acid cycle or the tricarboxylic acid 
cycle.  Acetyl-CoA is converted into citrate by citrate synthase, which is then 
transformed into cis-Aconitate and then D-isocitrate by aconitase the latter forming 
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NADH.  Α-KG is then formed using isocitrate dehydrogenase forming NADH; α-KG 
dehydrogenase then converts α-KG into succinyl-CoA by succinyl-CoA synthatase.  
The cycle continues forming succinate, fumarate and malate by succinyl-CoA 
synthetase, succinic dehydrogenase and fumarase respectively.  GTP is formed 
during the conversion of succinyl-CoA to succinate and FADH2 is formed in the 
conversion of succinate to fumarate. Malate dehydrogenase transforms malate in 
oxaloacetate forming NADH and finally this is converted into citrate by citrate 
synthase completing the cycle.  Intermediates of the Krebs cycle are used for 
macromolecule synthesis, citrate is exported for lipid synthesis and, α-KG and 
oxaloacetate are used to provide non-essential amino acids to build proteins and 
nucleotides, demand of which can have an impact on Krebs cycle function (Kaplan 
et al., 1993).  Glutaminolysis is able to maintain Krebs cycle activity when demand 
for intermediates for anabolic processes forming α-KG from glutamine to be used 
as a carbon source for the Krebs cycle (DeBerardinis et al., 2008, Obre and 
Rossignol, 2015).  NADH and FADH2, generated by the Krebs cycle, are utilised as 
electron carriers in the electron transport chain (ETC) during OxPhos.   
The Krebs cycle enzyme isocitrate dehydrogenase (IDH) which converts isocitrate 
into α-KG is implicated in cancer.  There are three isoforms; IDH1, IDH2 and IDH3.  
Mutations of IDH1 and IDH2 are common is various different cancers including; 
gliomas and acute myeloid leukaemia (Dang et al., 2010).  IDH1 resides prominently 
in the cytoplasm and reactions catalysed by IDH1 are reversible.  IDH2 and IDH3 are 
located in the mitochondrial matrix.  Reactions catalysed by IDH2 are reversible but 
IDH3 catalysed reactions are irreversible.  IDH3 can be activated by Ca2+, ADP and 
citrate, and it can be inhibited by ATP, NADH and NADPH (Losman and Kaelin, 
2013).    When mitochondrial glutamate levels are high, such as during hypoxia 
when glucose-derived citrate production is not optimal, glutamate is converted into 
α-KG by glutamate dehydrogenase (GDH).  This causes an increase in the α-KG: 
isocitrate ratio, and under these circumstances reductive carboxylation of 
glutamine into citrate catalysed by IDH2 is favoured to support hypoxic growth.  
This can also be observed in pseudo-hypoxic cells, which are von-Hippal Lindau 
(VHL) deficient (Gameiro et al., 2013).  IDH2 requires NADPH to work in reverse 
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mode; electrons can be transferred from NADH to NADP+ as there is a high level of 
NADH in hypoxic cells or those with a defective ETC.  This switch in IDH2 catalytic 
direction has been demonstrated in the glioblastoma cell line SF188 during hypoxia, 
along with an increase in 2-hydroxyglutartate (2HG) (Wise et al., 2011).  Another 
study using renal 143B cells, both WT and then a mutant deficient in the gene 
encoding cytochrome b (CYTB) (component of complex III of the ETC), showed cells 
with defective ETC preferentially use reductive carboxylation as a major pathway 
for production of fatty acids (Mullen et al., 2012).  It was also shown in the same 
study using UOK262 derived from a tumour in a patient with hereditary 
leiomyomatosis and renal cell cancer, that reductive carboxylation occurs in FH 
deficient cells.  Reductive glutamine metabolism can also be mimicked in cells with 
normal mitochondrial function, in this case mouse embryonic fibroblasts (MEFs) 
with the use of respiration chain inhibitors such as antimycin A or rotenone (Mullen 
et al., 2012).  
 
1.1.2 Oxidative Phosphorylation 
The OxPhos pathway consists of an ETC made up of five complexes (I-V), located on 
the inner mitochondrial membrane.  Complexes I, III and IV pump protons from the 
mitochondrial matrix into the intermembrane space, creating an electrochemical 
and proton gradient, the proton motive force (pmf), whereby the mitochondrial 
matrix is more negative inside (150mV) than the intermembrane space, as shown in 
Fig 1.2.  This gives a mitochondrial membrane potential (∆Ψm) which can be 
assessed (e.g. by staining with tetramethylrhodamine methyl ester (TMRM) to 
visualise the pmf, and ultimately mitochondrial function) (Leonard et al., 2015).  
Depolarisation of the ∆Ψm plays a role in apoptosis (Brand and Nicholls, 2011a).  
This gradient can be exploited by ATP synthase (complex V), which allows protons 
to move into the mitochondrial matrix providing energy for ADP + Pi to form ATP 
(Ferguson, 2000, Nicholls and Ferguson, 2013).      
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Figure 1.2 Schematic of the electron transport chain. Complexes I,III and IV pump 
protons across the inner mitochondrial membrane (IMM) into the intermembrane 
space, producing a proton motive force which is utilised by complex V (ATP 
synthase) to convert ADP into ATP.    
 
Complex I, also known as NADH-coenzyme Q oxidoreductase, is the first enzyme in 
the ETC, and catalyses the oxidation of NADH generated in the Krebs cycle and 
glycolysis.  Electrons from NADH are transferred to Coenzyme Q, thereby 
transferring four protons across the inner mitochondrial membrane (Chen et al., 
2010).  Complex II, sometimes referred to as succinate-Q oxidoreductase or 
succinate dehydrogenase is also a Krebs cycle enzyme that catalyses the oxidation 
of succinate to fumarate and reduces ubiquinone; this complex is not involved in 
the production of the proton gradient (Siebels and Dröse, 2013).  Co-enzyme Q then 
donates electrons to cytochrome b in Complex III, also called ubiquinol cytochrome 
c oxidoreductase, which catalyses the reduction of cytochrome c by the electrons 
donated from cytochrome b, along with four protons being pumped into the 
mitochondrial inter-membrane space (Bazil et al., 2013).   The terminal electron 
acceptor, Complex IV, also termed cytochrome c oxidase (COX), is where 
cytochrome c reduces cytochrome a3, consuming four protons in the process and 
reducing O2 to H2O.  Complex IV also pumps four protons across the inner 
mitochondrial membrane (Balaban et al., 2005).  Complex V, also known as ATP 
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synthase, then utilises this proton gradient generated to phosphorylate ADP 
creating ATP (Arnold, 2012).   
Studies have shown that ETC disorders may have a live birth prevalence of 1 in 
5000, with predicted figures of 13.1 in 100 000 live births affected and 1 in 7634 for 
ETC disorders with onset at any age (Skladal et al., 2003).  Diagnosis of these 
disorders is difficult, many symptoms overlap and some patients have multiple 
metabolic defects.  Deficiency in complex I, the most common of the respiratory 
chain complexes, manifests as Leigh syndrome, cardiomyopathy, stroke, lactic 
acidosis or ataxia (Calvo et al., 2010).  Complex II deficiency is very rare and not well 
defined (Jain-Ghai et al., 2013).   
Complex III can be pharmacologically inhibited using antimycin A (AA) blocking the 
Qi site, disrupting the internal transfer of electrons within the complex.  Mutations 
of the gene involved in the maturation of complex III, BCS1L, can cause Björnstad 
syndrome, a disorder in which there is abnormal hair and hearing problems, and 
GRACILE syndrome, which is a profound multisystem organ failure in which infants 
are not expected to live beyond a few months (Kotarsky et al., 2010, Hinson et al., 
2007).  In this disorder the BCS1L is broken down quickly, leading to a deficiency in 
complex III, especially in the liver and kidneys, which results in an energy deficit 
that damages the organs (Kotarsky et al., 2010, Hinson et al., 2007).   Cardiac 
dysfunction as a result of myocardial infarction can lead to decreased protein levels 
of complex III.  This was shown in mitochondria isolated from failing hearts in 
Wister rats; the degree of cardiac dysfunction dictated the level of mitochondrial 
impairment (Chinopoulos et al., 2010).   
Complex IV can be inhibited by cyanide, azide and carbon monoxide.  There are 
several genetic mutations that can occur in some of the assembly factors for 
complex IV including; Surfeit locus protein1, synthesis of cytochrome c oxidase 
(SCO) 1, SCO2, COX10, COX15, COX20, COA5 and leucine-rich PPR motif-containing 
protein (Rahman et al., 1996).  Associated disorders include; Leigh syndrome, 
cardiomyopathy, leukodystrophy, anemia and sensorineural deafness.  Leigh 
disease is one of the most common respiratory chain disorders, and is characterised 
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by a subacute necrotising encephalomyelopathy (Rahman et al., 1996).  Most cases 
are associated with a COX deficiency, but some have been reported to have 
pyruvate dehydrogenase complex deficiency/mutations or complex I deficiency 
(Rahman et al., 1996).   
ATP synthase deficiency is rare and can range in severity from mild cases causing; 
maternally inherited Leigh syndrome  or neuropathy, ataxia and retinis pigmentosa 
syndrome or severe cases such as, neonatal mitochondrial 
encephalo(cardio)myopathy (Jonckheere et al., 2012).  ATP synthase is also able to 
work in reverse mode in times of low pmf, working to restore the ∆Ψm which is 
achieved at the expense of ATP hydrolysis (Martin et al., 2014).  This process is 
regulated by the inhibitor protein IF1, which binds to the Fi domain of ATP synthase, 
selectively inhibiting reverse mode (Bason et al., 2014).  IF1 is activated when the 
pH becomes too acidic, below pH 6.5 and becomes inactive above pH 8.0 (Bason et 
al., 2014, Pullman and Monroy, 1963).  ATP synthase can be pharmacologically 
inhibited by oligomycin and is also implicated in intrinsic apoptosis.  The 
oligomycin-sensitivity conferring protein, a subunit of ATP synthase, is where 
cyclophilin D interacts and triggers the mitochondrial permeability transition pore 
(mPTP) to open, one of the stages in the mitochondrial apoptosis pathway (Antoniel 
et al., 2014).  It works by adjusting the Ca2+ level required for mPTP opening to 
occur (Bernardi, 2013). 
Both complex I and complex III have certain amount of proton leak which, 
combined with available O2, forms superoxide anion (O2·
-) (Balaban et al., 2005, 
Bandyopadhyay et al., 1999).  This is usually metabolised into hydrogen peroxide 
(H2O2) by superoxide dismutase (SOD).  If H2O2 comes into contact with a transient 
metal, a hydroxyl radical (OH·) is formed.   It has been shown, that in mitochondrial 
isolated from either the brain or heart of a SOD2 null mouse decreased complex II 
activity is present, which interestingly caused decreased reactive oxygen species 
(ROS) levels indicating that complex II is a major site for ROS generation 
(Chinopoulos, 2011).  Complex I is the most sparse of the ETC complexes with the 
quantity of each complex increasing from complex I to complex IV with ratios of 
complexes I, II, III, IV and ATP synthase shown to be 1.1 : 1.3 : 3.0 : 6.7 : 3.5 in 
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bovine heart mitochondria (Schägger and Pfeiffer, 2001).   ROS induces damage of 
the Fo complex , and is thought to be implicated in neurodegenerative diseases such 
as Parkinson’s disease, ischemia/reperfusion injury and atherosclerosis (Musatov 
and Robinson, 2012).   Increases in ROS and O2·
- can lead to the release of 
cytochrome c from the mitochondria, initiating apoptosis without the involvement 
of the mPTP (PETROSILLO et al., 2003).    
Low levels of ROS are important in multiple signalling pathways (Thannickal and 
Fanburg, 2000).  However, when levels become too high there are certain cellular 
defences against ROS which include a number of antioxidant enzymes, including 
SOD, catalase, Haeme peroxidases and glutathione peroxidase, which act as a first 
line of defence (Hayes and McLellan, 1999).  The second line of defence is provided 
by glutathione S-transferase, ascorbate, aldo-keto reductase and aldehyde 
dehydrogenase, which aim to protect cells from DNA, protein and lipid damage (Jo 
et al., 2001).  Products from ROS reacting with these enzymes are ejected from the 
cell via the glutathione S-conjugate transporter (Hayes and McLellan, 1999, 
Bandyopadhyay et al., 1999).  NADPH, which is required for the regeneration of 
glutathione from its oxidised to reduced form, is another crucial element in ROS 
scavenging (Jo et al., 2001).   Levels of ROS are often increased in cancer cells, 
however so are levels of ROS scavengers.  Many studies using antioxidants as 
cancer preventatives have shown little benefit or even detrimental effects (1994, 
Chandel and Tuveson, 2014).   
 
1.1.3 Cell Bioenergetics 
The area of cell bioenergetics has been studied for many years, and it is still of great 
importance today.  Cell metabolism can be altered in many ways, some of which 
are still unknown.  There are many drugs that can affect the mitochondria, and that 
would have repercussions on bioenergetics, including non-steroidal anti-
inflammatory drugs (NSAIDs) and anti-cancer treatments such as Tamoxifen 
(Mahmud et al., 1996, Mandlekar and Kong, 2001).  A bioenergetic approach can be 
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utilised in many treatment areas including anti-cancer therapeutics, stroke, and 
ischemia-reperfusion.   
Increased glucose utilisation is an accepted marker of certain cancers.  Increased 
glucose uptake has been exploited for diagnostic purposes in a clinical setting.  The 
technique is called positron emission tomography using 18F-fluorodeoxyglucose 
(FDG-PET) (Gatenby and Gillies, 2004, Semenza, 2010).  It has been shown to be 
useful in a number of different cancers, such as breast cancers, certain lymphomas, 
colorectal cancers and lung cancer (Alberini et al., 2009, Jerusalem et al., 2001, 
Fernandez et al., 2004, Machtay et al., 2013).  However as with all techniques FDG-
PET has its limitations. It shows areas with increased glucose uptake, including 
hypoxic regions where there is restricted O2 for OXPHOS and compensatory 
increases in glycolysis occur. However, hypoxic centres are often observed in solid 
tumours.   The method is unable to distinguish between readings from hypoxia 
fuelled increases in glucose uptake, and that driven by cancer.  There are also 
certain types of cancer which still gain much of their ATP from OxPhos, which has 
been shown using cervical carcinoma SiHa cells (Busk et al., 2008).   
Other biochemical intermediates are used clinically as diagnostic tools in oncology.  
Since the increase in glycolysis can be correlated with patient prognosis, the ratio 
between the mitochondrial enzyme ATP synthase and the glycolytic enzyme 
glyceraldehyde-6-phosphate dehydrogenase gives a bioenergetic index that can be 
used to assess tumour aggressiveness (Cuezva et al., 2002, Chacko et al., 2013).   
In each metabolic pathway there is spare capacity, which represents a potential for 
an increased rate of ATP generation.  For example in some cancerous tumours, the 
centre of the tumour becomes hypoxic (i.e. deprived of oxygen without a blood 
supply).  Under these conditions the concentration of O2 is inadequate for OxPhos 
to function at a normal rate, and the ATP deficit is rectified by up-regulation of 
glycolysis.   In hypoxic conditions the ∆Ψm can decrease, which may cause a degree 
of mitochondrial uncoupling, whereby the electrochemical gradient created by the 
ETC is altered (Aley et al., 2005).  As a result of this uncoupling, protons are able to 
cross through the inner mitochondrial membrane and  complexes I-V are inhibited 
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(Solaini et al., 2010).  This results in the cessation of OxPhos and causes ATP 
synthase/complex V to function in reverse mode to back pump protons out of the 
mitochondrial matrix, utilising ATP in an attempt to maintain the electron chemical 
gradient at the expense of ATP (Nicholls and Budd, 2000a, Bason et al., 2014).  This 
can occur naturally via activation of uncoupling proteins (UCPs) within cells, located 
on the mitochondrial inner membrane, which are able to dissipate the proton 
gradient, uncoupling the cell (Brand and Esteves, 2005).  These proteins, prevalent 
in brown fatty adipose tissue, can be activated in cold conditions to generate heat 
or by superoxide and activation can lead to decreased ROS levels, protecting the 
cell (Echtay et al., 2002, Brand and Esteves, 2005).  
Mitochondrial uncoupling causes the pmf to decrease, resulting in maximal 
respiration and a much lower rate of OxPhos.  The reduction in the ∆Ψm causes a 
number of changes including; reduced metabolite transport across the 
mitochondrial membrane, a decrease in mitochondrial and an increase in cytosolic 
Ca2+, activation of glycolysis, cytosolic acidification and dissipation of the 
mitochondrial ATP flux (Brand and Esteves, 2005).   
Pharmacological reagents such as cyanine-p-trifluoromethoxyphenylhydrazone 
(FCCP) or 2,4-dinitrophenol can induce mitochondrial uncoupling (Hynes et al., 
2006).  These reagents can cause maximal respiratory rates in the cell to be 
achieved (Hynes et al., 2006). Medicines including the diabetic drug, troglitazone 
and the statin, cerivastatin, have been withdrawn from the market as a result of 
organ toxicity associated with decreases in the ∆Ψm, which illustrates the 
importance of the investigation of mitochondrial uncoupling  (Bova et al., 2005, 
Kaufmann et al., 2006).  Mitochondrial uncoupling in certain metabolic conditions 
/ diseases can cause mitochondrial malfunction and ultimately cell death (Beeson et 
al., 2010, Chan et al., 2005). 
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1.2 REGULATION OF METABOLISM 
1.2.1 Metabolic Substrates 
Otto Warburg showed in the 1930’s that cancer cells have an altered metabolism 
compared to normal cells, exhibiting a substantially increased glycolytic activity, 
with an increased production of lactate from pyruvate instead of its conversion into 
acetyl-CoA and utilisation in the Krebs cycle producing reducing equivalents for 
OxPhos.  Warburg’s observations of the increased utilisation of glucose for 
glycolysis lead him to believe that the changes in cells which become cancerous are 
metabolic rather than genetic. The increased glycolytic rate occurs even when there 
are sufficient levels of oxygen for OxPhos and is sometimes referred to as aerobic 
glycolysis (Warburg et al., 1927).  This phenomenon is of importance, as OxPhos is a 
far more efficient, although slower way to generate ATP, creating approximately 36 
ATP molecules per molecule of glucose rather than a net of 2 ATP molecules 
created per molecule of glucose during glycolysis.   When cells predominately use 
glycolysis for metabolism, the pyruvate formed is converted into lactate in order to 
maintain sufficient NAD+ levels for glycolytic requirements (Lunt and Vander 
Heiden, 2011).  There are several factors which contribute to the Warburg effect, 
which include the transcription factor, HIF-1, oncogenic transcription factor MYC, 
oncogenic GTP-binding protein RAS, oncogenic non-receptor tyrosine kinase v-SRC, 
tumour suppressor transcription factor p53 and von Hippel-Lindau tumour-
suppressor protein (pVHL) (Dang and Semenza, 1999).  The increase in glycolytic 
activity in cancer cells has been shown to be strongly associated with hypoxia 
(Cairns et al., 2011).  However there are conflicting data, in a study analysing 32 
different cancer cell lines measuring lactate and O2 showing glycolytic and OxPhos 
contributions to ATP generation respectively, average glycolytic activity in cancer 
cells was shown to be very similar to that observed in normal cells.  However, the 
authors admitted the cells were not directly comparable and cells of the same 
tissue should be directly compared (Zu and Guppy, 2004).  There are cancer cells 
with functional mitochondria in which high levels of OxPhos are still present, 
observed in glioblastoma cancer stem cells, epithelial ovarian cancer stem cells and 
human breast cancer cells (Jose et al., 2011, Janiszewska et al., 2012, Pastò et al., 
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2014). It is thought that the cancer cells environment is an important factor in 
regulation of metabolism, it has been shown using HTB-126 human breast cancer 
cells that deprivation of glucose in cancer cells can increase OxPhos 5-fold, while O2 
deprivation can decrease OxPhos activity, this effect was not observed in non-
cancerous human breast (HTB-125) control cells (Smolkova et al., 2010). 
There are many oncogenic factors which when mutated can cause metabolic 
changes (Table. 1.1).  MYC is a constitutively expressed regulator gene that gains 
function in cancer, causing lactate dehydrogenase (LDH) expression to rise, and 
increasing glycolytic activity and lactate production (Dang and Semenza, 1999).  RAS 
is activated by mutations, gaining function in cancer.  It works to increase glycolysis 
and vascular endothelial growth factor (VEGF) expression (Dang and Semenza, 
1999).  V-SCR is an oncogenic retrovirally transduced gene that increases glycolysis 
and induces VEGF mRNA tHough HIF-1.  P53 is mutated in cancer causing HIF-1α to 
be stabilised, hexokinase II to be activated and induction of apoptosis under 
hypoxic and acidic conditions (Ke and Costa, 2006).  HIFs, pVHL and p53 will be 
discussed later. 
Table 1.1 Oncogenic factors which when mutated regulate different aspects 
of metabolism. 
Ocogenic Factor Mutational effect on metabolism  
MYC Increases glycolytic activity and lactate production through LDH 
up-regulation. 
RAS Increase glycolysis and vascular endothelial growth factor (VEGF) 
expression.   
V-SCR Increases glycolysis and induces VEGF transcription through HIF-1. 
 
P53 HIF-1α stabilisation, hexokinase II activation and induction of 
apoptosis. 
VHL HIF-1α stabilisation under normoxic conditions. 
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AMPK is a master metabolic regulator which plays a crucial role in cellular energy 
homeostasis, responding to changes in the AMP/ATP ratio (Yuan et al., 2013, 
Mihaylova and Shaw, 2011).   Activation of AMPK is achieved by AMP or ADP 
binding to the γ subunit causing a conformational change which allows 
phosphorylation to occur (Hardie, 2011).  Once active, AMPK switches on major ATP 
generating pathways whilst limiting energy consuming anabolic pathways, as shown 
in Fig 1.3.  It stimulates glycolysis by up-regulating the expression of glucose 
transporters (GLUT1 and GLUT4) and phosphorylates and activates 6-
phosphofructo-2-kinase which synthesises the glycolysis activator fructose-2,6-
bisphophate (Marsin et al., 2000).  AMPK also promotes fatty acid uptake and fatty 
acid oxidation and increasing mitochondrial biogenesis (Merrill et al., 1997, O’Neill 
et al., 2013).  Decreases in ATP utilisation occur from phosphorylation of acetyl CoA 
carboxylase (ACC1), inhibiting fatty acid synthesis, phosphorylation of glycogen 
synthase and reducing glycogen synthesis. It also results in inhibition of sterol 
regulatory element-binding protein preventing lipid synthesis and inhibition of 
gluconeogenesis (Hardie, 2011, Bultot et al., 2012).  AMPK is also involved in 
autophagy (Mihaylova and Shaw, 2011).  
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Figure 1.3 Schematic of metabolic pathway regulation. AMPK is activated when 
there is an increase in AMP or ADP.  Activation causes the inactivation of Acetyl CoA 
carboxylase (ACC), leading to a reduction in lipid metabolism.  AMPK activates 
tuberous sclerosis 1 (TSC1) which inhibits Rhed GTPase preventing mTORC1 
activation.  However activation of Akt by mTORC2, phosphoinositide-3-kinase (PI3K) 
or hypoxia can inhibit TSC1, allowing activation of mTORC1 which can activate the 
transcription factor hypoxia inducible factor 1α (HIF-1α). Both hypoxia and mitogen-
activated protein kinase (ERK) can also activate HIF-1α which has a number of 
downstream targets.   
 
Mammalian target of rapamycin (mTOR) is crucial element of cell growth and 
survival.  mTOR exists as two complexes mTORC1 and mTORC2 each with a 
different role (Xu et al., 2014).  mTORC1 plays a role in anabolic processes (e.g. 
protein synthesis) and is regulated by nutrients and growth factors.  mTORC2 
stimulates phosphoinsitide-dependent kinase 1, which activates the 
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serine/threonine kinase Akt, and in addition directly activates Akt by 
phosphorylation on Ser473 (Sarbassov et al., 2005, Porstmann et al., 2008, Yuan et 
al., 2013).  Akt is another cell metabolism regulator in the PI3K/Akt/mTOR pathway.  
Phosphoinoinsitide 3-kinase (PI3K) activates Akt which activates mTORC1 (Karar 
and Maity, 2011).  Akt is normally found in an inactive state, with expression 
induced by oncogenic factors.  Akt controls metabolism by stimulating glucose 
uptake by influencing the translocation of GLUT4 to the plasma membrane, 
increasing GLUT1 expression with a resultant increase in the expression of the 
enzymes involved in glycolysis and translocation of HKI/II to the mitochondrial 
outer membrane to increase glycolytic activity (Barnes et al., 2005).  This is 
summarised in Fig 1.3.   
There is also a phenomenon termed the Crabtree effect, whereby normal cells have 
depressed mitochondrial respiration as a result of increased glycolytic activity 
(Marroquin et al., 2007).  The effect can be reversed by switching the cell medium 
from one containing glucose to another that contains galactose, which causes no 
net gain of ATP to be derived from glycolysis and forces the cells back into 
generating ATP via OxPhos (Marroquin et al., 2007, Rossignol et al., 2004).    
In cancer cells, up-regulation of glycolytic activity occurs generally as a result of 
hypoxia.  Hypoxia up-regulates many genes that are involved in glycolysis, including 
those coding for glucose transporters, LDH, pyruvate dehydrogenase kinases (PDKs) 
and hexokinase II (Lu et al., 2008, Waters et al., 2014, Yasuda et al., 2004, 
Szablewski, 2013).  VEGF is also induced to promote angiogenesis (Yasuda et al., 
2004).  GLUT1 and GLUT5 are overexpressed in colon cancers (Pauwels et al., 2000, 
Szablewski, 2013).   
 
1.2.2 Starvation and Hypoxia  
Tumours often have a hypoxic centre which can lead to metabolic changes.  HIFs 
are stabilised under reduced O2 and become active transcription factors 
(mechanism discussed later).  This causes many survival and adaptive genes to be 
 
 
24 
 
induced or activated (Demidenko and Blagosklonny, 2011, Karar and Maity, 2011, 
Kim et al., 2006, Yee Koh et al., 2008).  HIF-1 expression, increased in hypoxia, 
causes increases in GLUT 1 and GLUT 3 as well as many of the enzymes crucial to 
glycolysis, such as phosphofructokinase L, aldolase A, (Glyceraldehyde 3-phosphate 
dehydrogenase) GAPDH, phosphoglycerate kinase 1, enolase 1and LDH A (Wenger, 
2002, Szablewski, 2013). 
In the inherited cancer, von HIppel-Lindau (VHL) disease, the pVHL tumour 
suppressor protein is mutated (Koh et al., 2008).  pVHL is involved in the 
degradation of HIF-α, so mutations causing a reduction in this proteins activity can 
lead to HIF-α stabilisation under normoxic conditions, as well as activation of genes 
for cell survival such as those encoding angiogenic factors such as VEGF (Cockman 
et al., 2000, Gameiro et al., 2013, Kamura et al., 2000).   
 
1.2.3 Metabolic Enzymes 
Pyruvate is the product of glycolysis and is pivotal in terms of metabolic pathways.  
There are two main routes pyruvate can take; it can either converted into acetyl-
coA by pyruvate dehydrogenase (PDH) resulting in oxidation to CO2, or it can be 
converted into lactate by LDH (Patel and Roche, 1990, Rardin et al., 2009).  Another 
possible pathway is the conversion into oxaloactate by pyruvate decarboxylase in 
an anaplerotic reaction aimed to replenish Krebs cycle intermediates such as 
alanine.  It has been shown that high HKII along with low pPDH expression in 
colorectal tumours was associated with increased aggressiveness and survival 
(Hamabe et al., 2014).   
The PDH complex is comprised of a catalytic PDH subunit (E1), a dihydrolipoyl 
acetyltransferase (E2), a dihydrolipoyl dehydrogenase (E3) and a E3-binding protein 
(E3BP) (Patel and Roche, 1990).  The PDH complex requires certain substrates are 
co-factors.  The PDH E1 subunit decarboxylates pyruvate uses thiamine 
pyrophosphate (TPP) as a cofactor; the remaining hydroxyethyl fragment is then 
transferred from TPP to lipoamide cofactor which is attached to E2 forming 
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acetyllipoamide.  All of these reactions are catalysed by the PDH E1 subunit.  Next 
E2 and E3 catalyse the transfer of the acetyl residue to coenzyme A regenerating 
lipoamide using FAD and NAD+ as a cofactor (Martin et al., 2005).   
The PDH complex is tightly regulated by phosphorylation/dephosphorylation 
reactions that occur on one of three serine residues on the Elα subunit, Ser-232, 
Ser-293 and Ser-300 and result in a change of metabolic fate for pyruvate (Rardin et 
al., 2009).  Instead of being utilised in the Krebs cycle providing intermediates for 
OXPHOS it can undergo gluconeogenesis to produce glucose in times of energy 
stress (Foretz et al., 2010).  Alternatively, in times of ischemic assault, it may be 
converted into lactate for metabolic fuel for oxidative cancer cells (Draoui and 
Feron, 2011).    
Activation of the PDH complex occurs via pyruvate dehydrogenase phophastase 
(PDP), which works to catalyse the de-phosphorylation of PDH, resulting in 
activation of the enzyme (Korotchkina and Patel, 2001, Pratt and Roche, 1979, 
Rardin et al., 2009).  There are two isoforms, PDP1 and PDP2, both of which are 
Mg2+ dependent (Lawson et al., 1993).  PDP is found loosely associated to the PDH 
complex, and only fully binds to the complex when activated.  Only PDP1 is 
activated by Ca2+, with maximal rate of PDP1 activity achieved at a mitochondrial 
Ca2+ concentration of approximately 3 µM (Turkan et al., 2004).  NADH inhibits 
PDPs activity (Huang et al., 1998).  PDP1 is highly expressed in the testes and 
skeletal muscle, while PDP2 is not, whereas in the kidneys and liver the reverse is 
true, with only PDP2 expressed in these organs (Huang et al., 1998).  Both PDP1 and 
PDP2 are expressed in the brain and heart.  Both PDP isoforms can be inhibited by 
NADH (Huang et al., 1998).   
PDKs are responsible for the phosphorylation/inactivation of the PDH complex, 
which means that they have a critical regulatory role in the bioenergetic fate of the 
cell.  PDKs exist as a homo- or hetero-dimer of various isoforms in their active state, 
depending on expression levels of the different isoforms (Abbot et al., 2005, Bao et 
al., 2004, Lu et al., 2008).  In order to inactivate PDH, PDK must bind to the inner 
lipoyl domain 2 or the outer lipoyl domain 1 of E2.  There are four isoforms of PDK 
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(1- 4), which have differential expression levels in different tissues.  PDK2 and PDK4 
are the prevailing isoforms in the heart and skeletal tissue, and these are also the 
only tissues in which PDK3 is expressed (Bowker-Kinley et al., 1998).  High levels of 
PDK2 are found in the heart, skeletal muscle and liver.  PDK4 can be found in high 
levels in the brain, kidneys and liver.  PDK1 is highly expressed in the heart (Bowker-
Kinley et al., 1998).  Both PDK1 and PDK3 are activated by HIFs during hypoxia, 
whereas, PDK2 and PDK4 are activated in times of metabolic and hormone 
deficiencies (Lu et al., 2008).  PDKs are active in their phosphorylated state.   All but 
PDK3 can be inhibited by high levels of pyruvate (Huang et al., 1998).  PDK3 has the 
highest activity of all PDKs and is found in very low levels in most tissues (Bowker-
Kinley et al., 1998).   All of the isoforms are controlled by metabolic by-products of 
PDH activity and can be inhibited by high levels of ADP, NAD+ and activated by high 
ATP, NADH, and acetyl-coA.  Increases in PDK2 and PDK4 can be observed upon 
glucose deprivation (Abbot et al., 2005).  PDK activity is increased in many different 
cancer cells (Board et al., 1990).  Therefore, activation of the PDK can be achieved 
pharmacologically using the pyruvate analogue dichloroacetate, which inhibits PDK 
(Pratt and Roche, 1979).  This is also a phenomenon that is prevalent in Alzeimers’s 
disease, diabetes and heart disease (Yao et al., 2009, Naik et al., 2012, Dugan et al., 
2013, Michelakis et al., 2008, Piao et al., 2010).    In these diseases, increased PDK 
levels cause decreased PDH activity and a decrease in mitochondrial biogenesis is 
observed.  Dichloroacetate has shown to increase PDH activity in PDH-deficient 
cells, however it should be noted that this was only in cells in which the mutation 
affected E1α stability (Fouque et al., 2003, Morten et al., 1999).   
There is a complimentary pairing whereby during starvation decreased PDP2 
expression levels occur together with an activation of PDK2 and PDK4 ensuring 
survival by hyper-phosphorylation of the PDH complex, to allow pyruvate to be 
conserved for use in gluconeogenesis if required.  This has been observed in 
diabetic patients (Huang et al., 2003) .  Activation of PDK2 and PDK4 occurs as a 
result of a build-up of acetyl-CoA and NADH from fatty acid oxidation, which 
promotes the binding PDK2 and PDK4 to PDH (Maj et al., 2006).   
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Pyruvate transport into the mitochondria is provided by the recently identified 
mitochondrial pyruvate carrier (MPC), which is located on the inner mitochondrial 
membrane (Bricker et al., 2012, Herzig et al., 2012).  Coupled to the electrochemical 
gradient, transport of pyruvate is associated with symport of one proton or 
exchange of one hydroxide ion.  The MPC complex is made up of one MPC1 core 
with several MPC2 subunits attached (Bricker et al., 2012, Herzig et al., 2012).   
In some cancers there are mutations in metabolic enzymes involved in the Krebs 
cycle or the ETC.  There are certain metabolic enzymes which act as tumour 
suppressors.  Two of these are the Krebs cycle enzymes fumarate hydratase (FH) 
and succinate dehydrogenase (SDH) (Selak et al., 2005).  Mutations in both of these 
enzymes can cause pseudo-hypoxia, activating HIF-α under normoxic conditions 
(MacKenzie et al., 2007).  SDH is also a part of complex II of the ETC, and mutations 
in this key enzyme are associated with hereditary paragangliona with 
phaeochromocytome, which arises from inhibition of prolyl hydroxylases (PHDs) 
causing HIF-α stabilisation as a result of decreased hydroxylation (Gottlieb and 
Tomlinson, 2005, Baysal et al., 2000).  There are two proposed methods of PHD 
inhibition, firstly by ROS created as a result of ETC malfunction without complex II.  
The second mechanism proposes a build-up of succinate in the mitochondria as a 
result of SDH not functioning properly and the conversion into fumarate not 
occurring, with the excess succinate being able to act as a secondary messenger, 
inhibiting PHD activity (Gottlieb and Tomlinson, 2005).  The latter is more likely to 
be the correct hypothesis as the same PHD inactivation occurs in hereditary 
leiomyomatosis and renal cell cancer caused by FH mutations, and FH is unlikely to 
be involved in ROS production (Gottlieb and Tomlinson, 2005, Tomlinson et al., 
2002).  In this case fumarate builds up as a result of FH mutations, causing the 
inhibition of SDH, thereby increasing succinate levels.  It has been shown that the 
inhibition of PHDs by both fumarate and succinate is α-ketoglutarate (α-KG) 
dependant.  Fumarate and succinate interfere with the binding of α-KG, which is a 
required co-substrate, to PHD (Selak et al., 2005).  Using cell-permeating α-KG 
derivatives, normal PHD activity can be regained and normal HIF-1α hydroxylation 
can occur (MacKenzie et al., 2007).   
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Another metabolic enzyme implicated in cancer is isocitrate dehydrogenase (IDH), 
which converts isocitrate into α-KG within the Krebs cycle.  There are three 
isoforms; IDH1, IDH2 and IDH3.  Mutations of IDH1 and IDH2 are common is various 
different cancers including; gliomas and acute myeloid leukaemia (Dang et al., 
2010).  IDH1 resides prominently in the cytoplasm and reactions catalysed by IDH1 
are reversible.  IDH2 and IDH3 are located in the mitochondrial matrix.  Reactions 
catalysed by IDH2 are reversible but IDH3 catalysed reactions are irreversible.  IDH3 
can be activated by Ca2+, ADP and citrate, and it can be inhibited by ATP, NADH and 
NADPH (Losman and Kaelin, 2013).    When mitochondrial glutamate levels are high, 
such as during hypoxia when glucose-derived citrate production is not optimal, 
glutamate is converted into α-KG by glutamate dehydrogenase (GDH).  This causes 
an increase in the α-KG: isocitrate ratio, and under these circumstances reductive 
carboxylation of glutamine into citrate catalysed by IDH2 is favoured to support 
hypoxic growth.  This can also be observed in pseudo-hypoxic cells, which are VHL 
deficient (Gameiro et al., 2013).  IDH2 requires NADPH to work in reverse mode; 
electrons can be transferred from NADH to NADP+ as there is a high level of NADH 
in hypoxic cells or those with a defective ETC.  This switch in IDH2 catalytic direction 
has been demonstrated in the glioblastoma cell line SF188 during hypoxia, along 
with an increase in 2-hydroxyglutartate (2HG) (Wise et al., 2011).  Another study 
using renal 143B cells, both WT and then a mutant deficient in the gene encoding 
cytochrome b (CYTB) (component of complex III of the ETC), showed cells with 
defective ETC preferentially use reductive carboxylation as a major pathway for 
production of fatty acids (Mullen et al., 2012).  It was also shown in the same study 
using UOK262 derived from a tumour in a patient with hereditary leiomyomatosis 
and renal cell cancer, that reductive carboxylation occurs in FH deficient cells.  
Reductive glutamine metabolism can also be mimicked in cells with normal 
mitochondrial function, in this case mouse embryonic fibroblasts (MEFs) with the 
use of respiration chain inhibitors such as AA or rotenone (Mullen et al., 2012).  
Glutamine is transported into the cell via the glutamine transporter SN1 or amino 
acid transporters ASCT1/ASCT2, and these all involve the co-transportation of Na2+.  
Glutamine, is then transported into the mitochondria by the mitochondrial 
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glutamine carrier (Albrecht et al., 2000), or converted into glutamate in the cytosol 
and transported into the mitochondria in a glutamate carrier or via a glutamate-
aspartate anti-porter, which is part of the malate-aspartate shuttle (Albrecht et al., 
2000).  Once in the mitochondria glutamine is converted into glutamate by 
glutaminase and then further transformed into α-KG which can be fed into the 
Krebs cycle.   
Glutamine plays a role in glucose regulation; α-KG produced via glutaminolysis and 
the Krebs cycle can activate glucose transport into the cell.  Alpha-KG causes the 
transcriptional repression of thioredoxin-interacting protein (TXNIP) via the 
activation of the transcriptional factor MondoA protein (Han and Ayer, 2013).  
TXNIP is a glucose sensitive MondoA target involved in a negative feedback loop 
restricting glucose uptake.  MondoA:MIX (Max-like protein X) complexes 
accumulate in response to high levels of intracellular glucose and repress TXNIP, 
which reduces glucose uptake (Stoltzman et al., 2011).  Ultimately glucose 
stimulates TXNIP activation and while glutamine represses this glucose fuelled 
activation, thereby increasing glucose transport into the cell (Stoltzman et al., 2011, 
Han and Ayer, 2013).   
 
1.2.4 Calcium and Calcium Transporters 
Calcium is important for many different cellular functions including; buffering 
system, secondary messenger, apoptosis and metabolism (Denton, 2009, Griffiths 
and Rutter, 2009, Nicholls, 2005, Orrenius et al., 2003, Tarasov et al., 2012).  Due to 
this Ca2+ needs to be stored and then mobilised when necessary.  Intracellular 
Ca2+ is stored predominantly within the endoplasmic reticulum (ER) and the 
mitochondria (Deng et al., 2009).  Mitochondrial Ca2+ is stored as a Ca2+ - phosphate 
complex within the matrix (Nicholls, 2005).  This complex is easily dissociable and 
the Ca2+ is liberated from the phosphate when there is a reduction in the ∆Ψm and 
exits the mitochondria via efflux transporters and the phosphates leaves via the 
phosphate transporter (Nicholls, 2005).   Ca2+ signalling and transporters are shown 
in Fig 1.4.   
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Figure 1.4 Schematic Ca2+ signalling and transporters. Voltage-gated Ca2+ channels 
(vGCC), N-methyl-D-aspatate (NMDA) receptors, nicotinic acetylcholine (n-Ach) 
receptors, and Orai are involved in Ca2+ entry into the cell.  The Na+/Ca2+ exchanger 
(NCX) and the plasma membrane Ca2+ ATPase (PMCA) are responsible for Ca2+ 
efflux.  Ca2+ is stored in the endoplasmic reticulum (ER) and can enter via stromal 
interation molecule (Stim) interacting with Orai forming a Ca2+ release-activated 
Ca2+ channel or  sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA).  Ca2+ is 
released from the ER via the inositol triphosphate (IP3) or ryanodine (Ry) receptors. 
The mitochondrial Ca22+ uniporter (MCU) is responsible for mitochondrial Ca2= influx 
and the mitochondrial Na+/Ca2+exchangerfor mitochondrial Ca2+ efflux.  Ca2+ is 
bound to Ca2+ binding proteins in the cytosol.   
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Rapid Ca2+ transmission is of great importance, mitochondria-associated 
membranes allow rapid transfer of Ca2+ from the endoplasmic reticulum (ER) to the 
mitochondria.  Activation of inositol triphosphate (IP3) or ryanodine receptors on 
the ER results in Ca2+ release into the mitochondria, which is taken up by Ca2+ 
uniporters (Hayashi et al., 2009).  Mitochondria-associated membranes are 
important for stimulation of oxidative metabolism, activation of manganese 
superoxide dismutase, ER stress and autophagy (Hopper et al., 2006, Hamasaki et 
al., 2013).   
Ca2+ plays a crucial role in excitable cells.  In neurons Ca2+ release triggers 
neurotransmitter release and synaptic plasticity, in myocytes within skeletal and 
cardiac tissue Ca2+ is necessary for muscle contraction (Holbro et al., 2009).  If the 
mitochondria become overloaded with free Ca2+ this can be the start of the intrinsic 
apoptotic pathway initiating programmed cell death (Fulda and Debatin, 0000).  
Increased mitochondrial Ca2+ levels activate the opening of the mPTP, which allows 
cytochrome c to be released binding with caspases forming the apoptosome 
initiating the caspase cascade resulting in apoptosis (Brunelle and Letai, 2009).   
Mitochondrial apoptosis can be driven by B-cell CLL/lymphoma 2 (BCL-2)proteins 
(Brunelle and Letai, 2009).    
Ca2+ can regulate metabolism, increases in intracellular Ca2+ can activate some 
metabolic dehydrogenases, PDH as well as the Krebs cycle enzymes isocitrate 
dehydrogenase and α-ketoglutarate dehydrogenase (Denton, 2009, Griffiths and 
Rutter, 2009).  Activation of these enzymes increases Krebs cycle activity, increasing 
NADH levels, providing more reducing intermediates for OXPHOS.  Ca2+ has also 
been shown to regulate key cell survival pathways.  Hypoxia inducible factor 1α 
(HIF-1α), can be regulated in an O2 independent manner by the receptor of 
activated protein kinase C (RACK1) pathway; in which dimerised RACK1 binds to 
HIF-1α in the presence of spermidine/spermine-N1-acetyltransferase 1, heat-shock 
protein 90 and the E3 ligase complex to promote HIF-1α degradation (Hawley et al., 
2005).  However calcineurin, a Ca2+ and calmodulin dependent phosphatase 
activated by Ca2+ can dephosphorylate RACK blocking the dimerisation required for 
RACK mediated HIF-1α degradation (Koh et al., 2008, Yee Koh et al., 2008).  In a 
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similar manner AMPK can be activated by Ca2+/calmodulin-dependant protein 
kinase (Hawley et al., 2005).   
When ER Ca2+ levels are decreased Ca2+ can enter the ER via the 
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), or stored operated 
channels which function through co-ordinated operation of stromal interaction 
molecule (STIM) and calcium release-activated calcium (CRAC) channel protein 
(Orai) and are ubiquitously expressed in both excitable and non-excitable cells 
(Deng et al., 2009, Mancarella et al., 2011).  Redistribution of the stromal 
interaction molecule (STIM), an ER Ca2+ sensor, occurs when ER Ca2+ levels are low, 
causing aggregation and translocation of these proteins to ER junctions where they 
couple with Orai which opens the newly formed CRAC channels allowing Ca2+ entry 
into the ER (Deng et al., 2009).  In times of oxidant stress or hypoxia this mechanism 
is inactivated and the STIM/Orai complexes uncoupled, caused by hypoxia induced 
decreased cytosolic pH, possibly protecting cells from Ca2+ overload (Mancarella et 
al., 2011).  As a result of which, upon hypoxia there is an increase intracellular 
Ca2+ concentration, which can increase Ca2+/calmodulin-dependant protein kinase 
activation of AMPK (Mungai et al., 2011).  It has been shown that Ca2+ is also able to 
regulate HIF signalling in a hypoxia independent manner by the receptor of 
activated protein kinase C (RACK1) pathway; in which dimerised RACK1 binds to 
HIF-1α in the presence of spermidine/spermine-N1-acetyltransferase 1, heat-shock 
protein 90 and the E3 ligase complex to promote HIF-1α degradation (Liu et al., 
2007).  However calcineurin, a Ca2+ and calmodulin dependent phosphatase 
activated by Ca2+ can dephosphorylate RACK blocking the dimerisation required for 
RACK mediated HIF-1α degradation (Koh et al., 2008, Yee Koh et al., 2008).   
1.2.4.1 Mitochondrial Transporters Controlling Calcium Fluxes 
There are many cellular Ca2+ transporters transporting Ca2+ into the cell; voltage-
gated Ca2+ channels, N-methyl-D-aspatate receptor, nicotinic acetylcholine receptor 
and transient receptor potential canonical, and out of the cell; Na+/Ca2+ exchanger 
and plasma membrane Ca2+ ATP-ase (Grienberger and Konnerth).  Calcium can then 
be either transported into the ER via ryanodine or inosoitol triphophate receptors 
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or into the mitochondrial via the mitochondrial calcium uniporter (MCU) 
(Grienberger and Konnerth, Mallilankaraman et al., 2012).   
Another Ca2+ transporter is the leucine-zipper-EF hand-containing transmembrane 
region Ca2+/H+ antiporter involved in Ca2+ influx.  The Ca2+/H+ antiporter transports 
Ca2+ in a 1:1 ratio with H+ efflux, it is electrogenic and so the H+ released from the 
mitochondria during respiration can drive mitochondrial Ca2+ entry (Santo-Domingo 
and Demaurex, 2010).  The Ca2+/H+ antiporter can be inhibited by ruthenium red 
(Santo-Domingo and Demaurex, 2010).   
The uniporter is located on the inner mitochondrial membrane and has a low 
affinity for Ca2+ (Mallilankaraman et al., 2012).  Uptake of Ca2+ is driven by ∆Ψm and 
uptake is able in part to control the rate of energy production by regulating certain 
enzymes (Denton, 2009, Griffiths and Rutter, 2009).  The MCU depends on a large 
electrochemical gradient to function (Mallilankaraman et al., 2012).  It was shown 
by Kirichok et al that the probability of the Ca2+ channel being open in cells with a 
∆Ψm of -200 mV was 99% whereas a reduced ∆Ψm of -80 mV had only 11 % 
probability of the MCU allowing Ca2+ entry into the mitochondria (Kirichok et al., 
2004, Hoffman et al., 2014).  The MCU is regulated by MICU1 and MICU2 (Patron et 
al., 2014).  MICU1 is involved in MCU opening in response to increases in 
extramitochondrial Ca2+ levels causing rapid increases in mitochondrial Ca2+ 
(Csordas et al., 2013).  Whereas, MICU2 has an inhibitory effect ensuring MCU has a 
low affinity for Ca2+, preventing Ca2+ cycling and possible overload (Mallilankaraman 
et al., 2012, Patron et al., 2014).   The MCU can be pharmacologically inhibited by 
ruthenium red (Mallilankaraman et al., 2012).   
The mitochondrial sodium/ calcium exchanger (NCLX) is responsible for 
mitochondrial Ca2+ efflux (Boyman et al., 2013, Palty et al., 2010).  It is localised to 
the inner mitochondrial membrane and has low affinity and high capacity for Ca2+ 
(Palty et al., 2010).  NCLX expression has been linked to enhanced mitochondrial 
Ca2+ efflux (Palty et al., 2010).  NCLX can be inhibited using CGP-37157 (Palty et al., 
2010).  The NCLX is electrogenic and is able to switch to reverse mode, pumping 
Ca2+ into the mitochondria and Na+ out, depending on the ∆Ψm and cytosolic and 
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mitochondrial matrix levels of Na+ (Kim and Matsuoka, 2008, Smets et al., 2004).  
Therefore under conditions where the ∆Ψm is depolarised the NCLX does not aid in 
mitochondrial Ca2+ efflux (Smets et al., 2004).    
 
1.3. CELL/TISSUE OXYGENATION AND HYPOXIA 
Oxygen levels can vary throughout tissue and vessels.  Physiologically normoxic O2 
concentrations across a range of tissues have a partial pressures in the range of 10-
45mmHg (Aragones et al., 2009).  Individual cells generally have a range of O2 
partial pressures between 10-20 mmHg (1.3 - 2.5 % O2) with mitochondria having 
O2 partial pressures under 10 mmHg (under 1.3 % O2) (Carreau et al., 2011).  
Oxygen gradients exist in tumours, the further the tumour is away from any blood 
supply the lower the O2 concentration will be, there are often regions with very low 
O2 concentrations almost reaching anoxia (Dmitriev et al., 2012).   
There can be variation within a tissue or cell monolayer, with oxygen gradients 
between the extracellular and intracellular regions of the cell (Dmitriev et al., 2012).  
For this reason, it is important to know where you are measuring.  There are a 
number of different approaches to quantify oxygen levels within tissues or cells.  
We can use oxygen sensitive probes to measure both intracellular and extracellular 
O2 levels (Fercher et al., 2011, O'Riordan et al., 2007, Zhdanov et al., 2010a, 
Dmitriev et al., 2012).  In many tumours there is poor vascularisation, leading to an 
inadequate supply of O2, which results in hypoxic regions.  Within these regions 
activation of a number of genes to aid in cell survival ensues, for example VEGF 
responsible for angiogenesis (Yasuda et al., 2004).   
In addition to being a critical area of research in the cancer field, hypoxia is of great 
importance to those studying ischemia/reperfusion which can occur as the result of 
a stroke, cardiac arrest, neonatal hypoxic–ischemic encephalopathy in infants from 
complications during labour (Sanderson et al., 2013).  The changes which occur as a 
result of ischemia cause damage, however the major injury is as a result of ROS 
created during reperfusion and opening of the mPTP following myocardial 
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ischemia/reperfusion (Schriewer et al., 2013).  During ischemia there is a cessation 
of OxPhos which causes a reduction in the ∆Ψm, depletion of ATP as a result, 
prevents ATP synthase working in reverse mode to restore the ∆Ψm (Sanderson et 
al., 2013).   Therapies to reduce ischemia/reperfusion induced damage centre 
around reducing ROS production, or increasing antioxidant levels (Cheng et al., 
2002, Valerio et al., 2011).  The levels of cytosolic and mitochondrial Ca2+ are of 
great importance during ischemia/reperfusion, when cytosolic Ca2+ increases the 
mitochondria uptake the excess Ca2+ which can drive the opening of the mPTP and 
initiate apoptosis (Davidson et al., 2012).   
P53, a tumour suppressor gene, has been implicated in many different cancers with 
a number of mutations in this gene are found (Muller and Vousden, 2013).  P53 is 
involved in many processes including; cell cycle arrest, senescence, apoptosis and 
DNA repair (Kelly et al., 2003, Muller and Vousden, 2013, Speidel, 2010).  P53 has 
been implicated to act both directly or indirectly with HIF in times of oxygen 
deprivation (Naito et al., 2010, Sermeus and Michiels, 2011).  Depending on the 
duration and level of hypoxia P53 levels have been shown to change, either 
increasing as a result of interactions with HIF-1α or murine double minute 2 or 
decreasing through carboxyl terminus of Hsp70-interating protein mediated 
degradation (Naito et al., 2010, Sermeus and Michiels, 2011). 
P53 accumulates as a result of DNA damage, hypoxia or oxidative damage and 
translocates to the mitochondria where it either inhibits or activates Bcl-2 family 
members (Speidel, 2010).  Bcl-2 is pro-apoptotic and if activated directly causes 
mitochondrial outer membrane permeablisation, triggering caspase release and 
initiating the caspase cascade, resulting in apoptosis (Speidel, 2010).  P53 facilitates 
apoptosis as a result of decreases in Guanosine-5'-triphosphate (GTP) after renal 
ischemia reperfusion in males Sprague-Dawley rats (Kelly et al., 2003).  
 
 
 
36 
 
1.3.1 HIFs  
In hypoxia many transcription factors are activated, the major ones being hypoxia 
inducible factors (HIFs).  HIFs exist as heterodimer complexes of α and β subunits,  
HIF-α levels are generally low under normoxic conditions as they are constantly 
degraded in the presence of O2 by prolyl hydroxylases (PHD1, 2 & 3), which 
hydroxylate two prolyl residues in the oxygen-dependant degradation domain 
(ODD), this process occurs rapidly (Jewell et al., 2001).  There are three isoforms of 
HIF-α, HIF-1α, HIF-2α and HIF-3α.  Hydroxylation under normoxia occurs 
predominately by PHD2 (Berra et al., 2003a), silencing of PHD2 is adequate to allow 
stabilisation of HIF-α under normoxic conditions, whereas knockdown of PHD1 or 
PHD2 is not (Berra et al., 2003b).  PHDs can be induced by HIF-1 creating a feedback 
loop.  This process in shown in Fig 1.5.   
Hydroxylated HIF-α undergoes proteasome-mediated degradation facilitated by 
VHL ubiquitin E3 ligase which tags HIF-1α with ubiquitin marking it for degradation 
(Pioli and Rigby, 2001).  PHD hydroxylation is O2 dependant, meaning HIF-α 
stabilisation occurs in hypoxic conditions.  HIF-β is constitutively active and is 
present in two forms, HIF-1β also known as the aryl hydrocarbon receptor nuclear 
translocator (ARNT1) and HIF-2β or ARNT2.  Once HIF-α is stabilised, it is 
translocated into the nucleus where is dimerises with HIF-β to form an active 
transcription factor which can go on to induce many cell survival and adaptation 
genes needed in order for the cells to survive the hypoxic environment.  In hypoxic 
conditions oxygen levels decrease along with the activity of PHDs, allowing HIF-1α 
to accumulate (Demidenko and Blagosklonny, 2011), shown in Fig 1.5.   
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Figure 1.5 Schematic of HIF signalling under normoxia and hypoxia. Under 
normoxia HIF constantly undergoes proteosomal-mediated degradation.  In the 
presence of O2 prolyl hydroxyalses (PHDs) hydroxylate two prolyl residues in the 
oxygen-dependant degradation domain of HIF.  Once hydroylated, von Hippel-
Lindau (VHL) ubiquitin E3 ligase tags HIF-1α with ubiquitin marking it for 
degradation proteasome-mediated degradation.  Under hypoxic conditions the O2 
dependant PHDs no long function, meaning there is no VHL binding and HIF-α iss 
stabilised.  Once stabilised HIF-1α will translocate to the nucleus where it will form a 
dimer with HIF-1β.  HIF-1α which has not undergone hydroxylation allows CREB-
Bind protein/p-300 (CBP/p-300) recruitment, resulting in gene transcription.    
 
Once activated HIFs are involved in the activation of a number of metabolic 
proteins including; GLUT1 and GLUT3, phosphofructokinase L, aldolase A, 
(Glyceraldehyde 3-phosphate dehydrogenase) GAPDH, phosphoglycerate kinase 1, 
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enolase 1and LDH A (Wenger, 2002).  HIF activation also stimulates numerous 
angiogenic factors such as VEGF providing blood supply and nutrients to a tumour.  
Both VEGF and erythropoietin (EPO) are expressed in neurons and are both 
neurotrophic and neuroprotective (Brines et al., 2000, Góra-Kupilas and Josko, 
2005, Morishita et al., 1997, Storkebaum et al., 2004).  However their roles are not 
only in the central nervous system, increases in mRNA expression of both EPO and 
VEGF have been implicated in persistent pulmonary hypertension of the newborn 
(PPHN) and cyanotic congenital heart disease (CCHD) (Lemus-Varela et al., 2010).    
The VEGF family has a number of members, VEGF A-F and placenta growth factor 
(PIGF) (Keifer Jr et al., 2014).  These are involved in angiogenesis, neuronal 
development, lymphangiogenesis and vascular permeability (Keifer Jr et al., 2014).   
VEGF plays an important role in response to ischemia in conditions such as heart 
disease or stroke (Liu et al., Lemus-Varela et al., 2010).  VEGF gene therapy is 
currently under investigation for a number of conditions including: myocardial 
ischemia, amyotrophic lateral sclerosis (a progressive neurodegenerative disease), 
cerebral ischemia and peripheral arterial disease (Won et al., 2013, Keifer Jr et al., 
2014, Isner et al., 1996).   
EPO initially discovered as a hematopoietic growth factor is also regulated by HIF.  
EPO is of great importance to cardiac adaptation under hypoxia, both acute and 
chronic, through HIF-1α transcription (El Hasnaoui-Saadani et al., 2013).  In normal 
physiology the kidney has renal EPO producing cells which are increased in number 
in response to decreases in O2, in an oxygen dependent manner (Haase, 2013).  
During embryogenesis the liver is the primary site for EPO production, a function 
which is maintained in adults and EPO is produced in response to hypoxia or 
pharmacological induced HIF induction (Fried, 1972, Haase, 2013).   
Translation of HIFs can be upregulated by Akt and Erk pathways (Koh et al., 2008).  
HIF-2α has been shown to be dependent on Akt2 and HIF-1α dependent on Akt3 
(Toschi et al., 2008).     AMPK is stimulated under hypoxic conditions inhibiting the 
activity of mTOR, a crucial element of cell growth and survival, which affects protein 
synthesis and transcription, thereby decreasing HIF production (Liu et al., 2006).  
 
 
39 
 
The activity of both HIF-1 and HIF-2 is dependent on mTOR, which is the catalytic 
subunit of mTORC1 and mTORC2, while HIF-1α requires both of these complexes 
for activation; mTORC2 is the only essential component for HIF2α activation (Toschi 
et al., 2008).    mTORC1 is involved in anabolic processes, such as protein synthesis 
and is regulated by nutrients and growth factors.  mTORC2 activates 
phosphoinsitide-dependent kinase 1 which can activate the serine/threonine kinase 
Akt  (Sarbassov et al., 2005, Porstmann et al., 2008, Yuan et al., 2013).   Akt is an 
important metabolic regulator which can increase glucose uptake by inducing 
GLUT4 translocation and GLUT1 expression, it can also activate mTORC1, 
influencing HIF-1α activity (Karar and Maity, 2011).   
HIF has been implicated in cancer and is correlated with a poor prognosis (Dong et 
al., 2013, Wan et al., 2010, Span et al., 2011).   Tumours often have a hypoxic 
centre which can lead to metabolic changes.  Metabolic substrates play important 
roles in cancer cells during hypoxia, high levels of glycolysis and glutaminolysis are 
important for cell survival.  Glutamine and glucose are important in HIF-signalling 
during hypoxia, deprivation of one or both of these substrates can lead to inhibition 
of HIF-1α accumulation under hypoxic conditions (Kwon and Lee, 2005).  Under 
glucose and oxygen deprivation, down-regulation of HIF signalling occurs as a result 
of depleted ATP levels, causing disruption of translational processes (Zhdanov et al., 2013).  
Increased expression of HIF-2α is observed in PC12 cells, and is strongly associated 
with development of pheochromocytoma (Span et al., 2011).   
 
1.4. METHODS OF ASSESSMENT OF CELL METABOLISM AND BIOENERGETICS 
Metabolic assessment can be used to perform toxicity testing, which is of vital 
importance for any potential therapeutic agent and in order to comply with 
regulations.  Scientists need to be able to reduce the number of animals used, 
refine experiments so no unnecessary pain is caused to animals, using other means 
of testing materials.  There is also a need to test non-lethal effects that compounds 
may have on cells, assessing the metabolic changes that may occur within the cell.  
There are many drugs that are known to cause mitochondrial toxicity, including 
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some chemotherapeutic agents, antibiotics and antiretroviral drugs.  There are 
many different ways in which drug-induced mitochondrial toxicity can occur; 
inhibition of ETC complexes can occur by drugs such as antipsychotics or local 
anaesthetics.  Mitochondrial toxicity can also be as a result of: ROS generation from 
doxorubicin, disruption to mitochondrial protein synthesis and biogenesis by 
antivirals or uncoupling reagents such as NSAIDs (Chan et al., 2005).   
Mitochondrial toxicity can go undetected using tradition methods such as ATP, MTT 
and LDH assays.  These assays only work to test cell viability; a compound may In 
fact be toxic but not lead to apoptosis or necrosis.  Mitochondrial toxicity is one of 
the causes of late stage drug attrition in the pharmaceutical industry, so methods to 
assess this characteristic at an early stage of drug development are important 
(Zhang et al., 2009).   
The cell energy budget (CEB) platform has many applications; it can be used to 
perform toxicity testing, to differentiate the utilisation of different metabolic 
pathways (bioenergetics), and to perform in-depth metabolic studies.  The CEB 
system can determine the contributions of the main metabolic pathways of OxPhos, 
Krebs cycle and glycolysis to ATP production.  The platform uses O2 and pH sensitive 
probes to assess the different metabolic pathways (Hynes et al., 2009a, O'Riordan 
et al., 2007, Zhdanov et al., 2011b).   
Both within our lab and outside, it has been shown that the CEB platform can be 
used to assess mitochondrial toxicity in both eukaryotic cells and bacteria (Hynes et 
al., 2006, Jasionek et al., 2010, Bansal et al., 2013, Beeson et al., 2010).   
 
1.4.1 Traditional methods 
Earlier research consisted of measurement on both intact cells and isolated 
mitochondria in vitro. Measurements include: trypan blue exclusion, NAD(P)H, ATP, 
ADP/ATP ratio, pmf, ∆Ψm, Ca
2+ and ROS fluorescent indicators (Kadish et al., 1968).  
These measurements do not give information on the contribution of different 
metabolic pathways and may miss changes due to compensatory up-regulation of 
 
 
41 
 
other metabolic pathways, for example in the case of mitochondrial toxicity up-
regulation of glycolysis occurs to compensate for decrease OxPhos.      
Previous oxygen consumption methods used O2 electrodes to measure reductions 
in dissolved O2.  The Clark type O2 electrodes are comprised of a platinum cathode 
and anode connected via an electrolyte solution (Brand and Nicholls, 2011b).  
Reduction of O2 results in an electrical current which can then be converted into a 
concentration of dissolved O2 (Brand and Nicholls, 2011b).  For this technique 
isolated mitochondria are used and manipulations are performed.  Addition of ADP 
is used to achieve state 3 respiration which can be used as a measure of OxPhos 
capacity.  State 4, a resting rate of respiration can be accomplished by adding 
oligomycin to eliminate ATP turnover (Rosenthal et al., 1987, Berman and Hastings, 
1999).  A final State 3,  in which a rate of uncoupled respiration can be measured is 
provided by FCCP treatment (Rosenthal et al., 1987, Berman and Hastings, 1999).  
With these measurements the respiratory control rate (RCR) can be calculated 
which is the rate of state 3 respiration divided by the rate of stage 4 respiration 
(Rosenthal et al., 1987).  The main disadvantage is that this technique is 
predominately performed on isolated mitochondria and a constant stirring of the 
sample is required.  
The use of intact cells provides a more informative and complex picture of events 
with greater physiological relevance.  Fluorescence live cell imaging can allow 
monitoring of ∆Ψp, ∆Ψm and Ca
2+ or ROS indicators (Zhdanov et al., 2011a, Zhdanov 
et al., 2010b).   
Colourmetric techniques are available for glucose measurement using an enzymatic 
procedure studying glucose oxidation by glucose oxidase (Kadish et al., 1968).  
Glycolytic activity can be estimated measuring ATP levels with the ATP synthase 
inhibitor, oligomycin.  The level of respiration decreases and the rate of glycolysis is 
up-regulated, in this case the majority of ATP produced will be from glycolysis 
(Brand and Nicholls, 2011b).  Oligomycin blocks the transport of protons through 
ATP synthase, thereby inhibiting ATP production via OxPhos.   
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Glycolytic rates can be assessed in perfused heart tissue by monitoring 3H2O 
production from [5-3H/U-14C]-glucose addition.  Metabolism causes 3H to be 
transformed into water and labelled glucose to be converted into glucose-6-
phosphate (Neely et al., 1972).  14CO2 and 
3H2O production can be measured 
determining glucose oxidation and glycolysis respectively (Lopaschuk et al., 1993).  
Another measure of glycolytic activity is to measure glucose uptake using the radio-
labelled glucose analog 2-deoxyglucose which can be metabolised into glucose-6-
phosphate (Zhao et al., 2008).  This technique can be performed on both adherent 
and non-adherent cells (Zhao et al., 2008).  Measurement of glucose transporters 
can provide information about glucose uptake, GLUT1 protein levels can be 
accessed via Western blot.  Increased GLUT1 protein levels can indicate increased 
levels of glycolysis, it is also a commonly used hypoxia marker, increased in O2 
deprivation conditions (Meijer et al., 2012).      
Assessment of the pmf can also give indications as to mitochondrial activity.  It is 
split into two components, ∆Ψm and pH gradient, the former is more dominant 
contributor (Brown and Brand, 1986).  Experiments using the ionophore nigercin 
allow measurement of pmf solely from ∆Ψm.  Indirect methods are required to 
measure ∆Ψm which involve adding lipophilic membrane-permeant cations, such as 
TPP+ (tetraohenylphophonium ion) monitoring cation uptake via fluorescence or 
absorbance (Brown and Brand, 1986).   
 
1.4.2 New approaches 
Each metabolic pathway has a considerable spare capacity which can be utilised 
when another pathway is not functioning optimally or in times of increased energy 
demand.  A schematic of the interconnecting metabolic pathways is shown below is 
Fig. 1.6, which illustrates how each metabolic pathway does not work to full 
capacity.  Therefore one pathway can increase ATP production to compensate for 
decreased ATP synthesis by another to maintain constant ATP levels.  As shown in 
Fig. 1.6, lactate levels give an indication to glycolytic activity; CO2 levels can show 
Krebs cycle activity and measuring O2 levels and the oxygen consumption rate 
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(OCR), the contribution of OXPHOS to ATP production can be elucidated.  The 
relative contribution of glycolysis, Krebs cycle and OxPhos varies between cell types 
and conditions.  Metabolic malformations or disorders can result in altered 
metabolic pathway contributions.   
  
Figure 1.6.  Diagram of the main metabolism pathways in mammalian cells.   
Metabolic pathways work together to maintain a constant supply of ATP for the cell.  
Each pathway has a spare capacity which can be utilised in times of energy stress in 
other metabolic pathways.  For example in hypoxia where OxPhos is down regulated 
glycolysis is up-regulated to maintain constant ATP levels within the cell.    
 
New approaches for measuring metabolic pathways within cells give a more 
comprehensive overview of cellular metabolism.  One more modern approach is 
the XF system in which mitochondrial respiration and glycolysis in live cells can be 
measured using solid-state sensors, enabling the measurement of both OCR and 
ECA simultaneously (Laderoute et al., 2014).  One disadvantage of this system is 
that it is costly, a special machine (XF analyser) with XF microplates has to be 
purchased to use this system (Invernizzi et al., 2012, Wu et al., 2007).   
There are several systems available for measuring respiratory activity in cells by 
optochemical sensing approaches (Domenis et al., 2011, Gero et al., 2014, Comelli 
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et al., 2011).  One such system allows O2 measurement in differing O2 ranges from 
physiological down to hypoxic levels (Trumbeckaite et al., 2013).  This system can 
also be combined with fluorometry allowing measurement of ROS, Ca2+, ATP, pH or 
∆Ψm.  This system is also expensive, requiring the purchase of a special Oxygraph-2k 
instrument (Trumbeckaite et al., 2013, Comelli et al., 2011).  Within our lab, the CEB 
platform has been developed which is a useful series of methods for investigation 
of perturbed metabolism and mitochondrial and glycolytic disorders.  With this 
system investigation of changes in the contribution of different metabolic pathways 
to ATP generation by studying various fluxes of each system is possible (Zhdanov et 
al., 2011a, Zhdanov et al., 2011b).   
In our system the level of cellular respiration can be assessed by measuring oxygen 
levels using either extracellular or intracellular Pt-porphyrin based phosphorescent 
probes (Dmitriev et al., 2012, Fercher et al., 2011). Optical signals of these probes 
can be read conveniently in standard 96 well microtitter plates on a conventional 
time–resolved fluorescence plate reader.  Phosphorescence intensity values 
measured at two delay times can be converted into lifetime (LT) values (Eq. 1.1) and 
then into O2 concentration or OCR values with an equation obtained from probe 
calibration (Eq. 1.2 and 1.3) as shown in Fig 1.9.  The probes are reversibly 
quenched by O2, so as the O2 levels in the sample are depleted by cellular 
respiration probe signal increases.   
τ = (t2 – t1) / ln(F1/F2)                      (Eq. 1.1) 
For the intracellular O2 probe MitoXpress-Intra®, loading occurs as shown in Fig. 
1.7.  O2 is calculated using eq. 1.2 which was obtained from calibrations performed 
in the laboratory. O2 is calculated as µM per well in a 96 well plate, 4-8 wells are 
used per condition and at least 3 repeat experiments are conducted and the 
averages calculated.  
O2 = 18576 exp(−LT/6.8794)    (r
2 = 0.9863) (Dmitriev et al., 2012)                                                  
(Eq. 1.2) 
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Figure 1.7.  Diagram of well in a 96 well plate loaded with MitoXpress-Intra.   
The MitoXpress-Intra probe is a cell penetration nanoparticle probe.   
MitoXpress-Xtra® extracellular O2 probe (OCR measurement), loading occurs as 
shown in Fig.1.8 and O2 is calculated using: 
O2 = 4455.46 exp(−LT/7.482 84)    (r
2 = 0.993 25) (Dmitriev et al., 2012)                                        
(Eq. 1.3) 
 
Figure 1.8.  Diagram of well in a 96 well plate loaded with MitoXpress-Extra.   
The MitoXpress-Extra probe is located in the media and the well is sealed with 
mineral oil to prevent O2 diffusion.   
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Figure 1.9.  Processing OCR data A.  Raw phosphorescence lifetime (LT) values 
for MEF cells treated with water (control), AA (antimycin A) (negative control) and 
test sample (PEG1100 NP).  AA treatment inhibits respiration giving the lowest LT 
and highest O2 value.  LT Values are then converted into B.  Extracellular O2 values 
using equation 1.3 obtained from calibration. AA values are steadily maintained at 
200 µM showing no oxygen consumption, PEG1100 treated cells have a steeper rate 
of O2 consumption compared with the control.   C.  The slopes are then calculated 
and OCR determined, these show the greater OCR in the PEG1100 treated cells 
compared with the control indication up-regulation of OxPhos under these 
conditions.   
 
The level of cell oxygenation is inversely related to the respiratory activity.  The 
measurement of extracellular O2 allows assessment of the oxygen consumption 
rate (OCR) whereas measuring intracellular O2 provides  accurate quantitative real-
time intracellular O2 values, whilst allowing transient changes to be observed 
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(Dmitriev et al., 2012, Fercher et al., 2011, O'Riordan et al., 2007, Zhdanov et al., 
2011b).    
Using the CEB platform, extracellular acidification (ECA) is measured using a long-
decay emitting pH-sensitive lanthanide probe.  There are two assay formats used, 
lactate-related (L-ECA) and total-ECA (T-ECA). In the T-ECA a layer of heavy oil 
covers the wells of on the 96 well plate and combined extracellular acidification 
generated by CO2 from the Krebs cycle and as a result of lactate production from 
glycolysis is measured.  It should be noted that small amounts of CO2 are also 
produced from the pentose phosphate pathway (Wamelink et al., 2008).   L-ECA 
performed without oil allows CO2 to escape in the atmosphere, measuring only the 
contribution of lactate to extracellular acidification, as shown in Fig.1.10 (Hynes et 
al., 2009b, Zhdanov et al., 2011b).  With dual measurement of L-ECA and T-ECA the 
contribution of glycolytic and non-glycolytic ECA can be elucidated.  The 
phosphorescence LT of the pH-Xtra probe increases with [H+] elevation and 
decreased pH.  The resulting LT signals can be converted into pH values using Eq. 
1.4, obtained from probe calibrations. 
pH = (1893.4-LT)/227.54                                                                                            (Eq. 1.4) 
 
Figure 1.10.  Diagram of wells in a 96 well plate loaded with pH-Extra.   
Lactate-ECA (L-ECA) had an open system and the probe is in the media, however 
total-ECA (T-ECA) a layer of mineral oil seals the well preventing Co2 diffusion 
allowing measurement of lactate and Co2.   
pH is then converted into H+ and the rate calculated.   
The CEB measurements are usually combined with ATP assessment using a 
luminescent kit (Promega CellTiter-Glo®Luminescent Viability Assay).  Together with 
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ATP measurement, the CEB platform allows real time measurement of metabolic 
changes.  Stimulations with pharmacological reagents which allow maximal (FCCP) 
and minimal (AA) respiration to be observed and which also shifts glycolytic 
pathway function.  Oligomycin can be used to inhibit OxPhos by blocking ATP 
synthase function; however this causes an increase in pmf.  Dual treatment of 
FCCP/oligomycin allows respiratory activity with uncoupled mitochondria to be 
assessed without compensatory hydrolysis of ATP by ATP synthase to maintain 
∆Ψm.   
As demonstrated by the investigation of the role of enzyme fumarate hydratase 
(FH) in cellular ATP production using FH knockdown MEF cells, the CEB platform is 
an effective tool for assessing mitochondrial defects (O'Flaherty et al., 2010).   A 
striking decrease in oxygen consumption was observed in FH-/- cells compared with 
wild type (WT) cells.  Uncoupling of these cells did not increase OCR but a two fold 
increase was seen in WT cells (O'Flaherty et al., 2010).  A compensatory increase in 
glycolytic flux was observed in these cells, illustrated by increase L-ECA, which 
increased further upon uncoupling of the mitochondria (Zhdanov et al., 2011b).  
Manipulation of culture medium (glucose + or -) was able to distinguish differences 
in ATP responses in FH-/- and WT cells (O'Flaherty et al., 2010).  These results show 
practical use of the CEB platform for bioenergetics research.   
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2.1  MATERIALS  
O2-sensitive probes MitoXpress®-Xtra, MitoXpress®-Intra NanO2 and pH-sensitive 
probe pH-Xtra were from Luxcel Biosciences (Cork, Ireland). Glutaminase inhibitor, 
BPTES (bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide) was kindly 
provided by Dr. Takashi Tsukamoto (John Hopkins University, MD). Mitochondrial 
membrane potential indicator Tetramethyl rhodamine methyl ester (TMRM), 
Lipofectamine 2000 and Opti-MEM I were from Invitrogen Life Technologies 
(Carlsbad, CA). Plasma membrane potential indicator (PMPI) was from Molecular 
Devices (Sunnyvale, CA). Amersham ECL Prime Western blotting reagent was from 
GE Healthcare Life Sciences (Waukesha, WI), pre-made acrylamide gels, running 
and transfer buffers were from GeneScript (Piscataway, NJ), PhosStop Phosphatase 
Inhibitor and complete Protease Inhibitor Cocktail Tablets were from Roche 
(Ireland), BCA™ Protein Assay kit and PageRuler Plus Prestained Protein Ladder 
were from Thermo Fisher Scientific (Rockford, Ill). The mitochondria-targeted Ca2+ 
biosensor, mitoCase12 was from Evrogen JSC (Moscow, Russia). CellTiter-Glo® ATP 
Assay was from Promega (Madison, WI). Mineral oil (type 37) was from Cargille 
Laboratories (Cedar Grove, NJ). SMARTpool: ON-TARGETplus PDK1 siRNA  and ON-
TARGETplus Non-targeting siRNA #1 from Dharmacon, Thermo Scientific.  SV Total 
RNA Isolation System, ImProm-II™ RT System and PCR Master Mix were from 
Promega (Madison, WI). Dulbecco's Modified Eagle's medium (DMEM) and Roswell 
ParkMemorial Institute (RPMI) media, McCoy’s 5A modified media, nerve growth 
factor (NGF), collagen IV, FCCP, D-glucose, D-galactose, L-glutamine, sodium 
pyruvate, HEPES, fetal bovine serum, horse serum, oligomycin, antimycin A and 
other reagents were from Sigma-Aldrich. 
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Table 2.1 Cell seeding densities used.   
 
Cells 
 
96 well 
(cells/well) 
 
12 well 
(cells/well) 
6 well (cells/well)  
1 cm2 dish 
(cells/dish) 
20.9% 
O2 
3%  
O2 
PC12 5*104 5*105 n/a n/a 2.5*104 
MEF 4*104 n/a n/a n/a n/a 
HCT116  4*104 n/a 1.2*105 3*105 1.5*104 
HCT116 SCO2-/- 4*104 n/a 2*105 3*105 2.2*104 
 
 
Table 2.2 Constituents of working media.  Nerve growth factor was only added 
to media used for PC12 cells to cause differentiation in these cells making them a 
neuronal cell modal.  All media were serum-free and all but the media used for 
ECA experiments contained 20 mM HEPES (pH 7.2).   
Components Working media 
 1 2 3 4 5 6 7 8 9 10 11 12 
10 mM D-glucose + + + +         
10 mM D-galactose     + + + +     
2 mM L-glutamine + +   + +   + +   
1 mM Pyruvate  + +   + +   + +  
100 ng/ml Nerve 
growth factor 
+ + + + + + + + + + + + 
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Table 2.3 Cellular stains for microscopy measurements.     
Probe Concentration Function Staining Procedure Excitation, 
emission 
Mitocase12 5 ng/ml Stains 
mitochondrial 
Ca2+  
Lipofectamine 
transfection 
488nm, 500-
540nm 
Fluo4-AM 2.5 µM Stains 
cytosolic Ca2+ ` 
Add 2.5 µM for 60 
min, wash, leave for 
30 min and measure 
488nm, 500-
540nm 
TMRM 20 nM Stains ΔΨm Add 20 nM 30 min 
prior to measurement 
543nm, 555-
600nm 
PMPI 20 nM Stains ΔΨp Add 20 nM 30 min 
prior to measurement 
543nm, 555-
600nm 
JC1 2.5 µM Stains ΔΨm Add 2.5 µM for 30 
min, wash and 
measure 
488nm, 500-
540nm 
mtAlpHi 5 ng/ml Intracellular 
pH 
Lipofectamine 
transfection 
 
488nm, 500-
540nm 
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Table 2.4 Antibodies used for Western blotting 
Antibody M.W. 
(kDa) 
Secondary Company 
HIF-1α 118 Goat R & D 
HIf-2α 120 Mouse R & D 
pPDH E1-α subunit (Ser293) 43 Rabbit Abcam 
PDH E1-α subunit 43 Mouse Abcam 
PDK1 60 Rabbit Cell Signaling 
LDHa 37 Rabbit Cell Signaling 
p-AMPK (TH172) 62 Rabbit Cell Signaling 
AMPKα 62 Rabbit Cell Signaling 
LC3A/B 14, 16 Rabbit Cell Signaling 
PARP 89, 116 Rabbit Cell Signaling 
Cleaved caspase 3 17, 19 Rabbit Cell Signaling 
mTOR 289 Rabbit Cell Signaling 
p-mTOR (Ser2448) 289 Rabbit Cell Signaling 
p-Akt (TH308) 80 Rabbit Cell Signaling 
p-Akt (Ser473) 80 Rabbit Cell Signaling 
p-p44/p42 MAPK (Erk1/2) 
(TH202/Tyr204) 
44, 42 Rabbit Cell Signaling 
VDAC 31 Goat Santa Cruz 
Α-tubulin 55 Mouse Sigma 
 
 
Table 2.5 Immunostaining Antibodies 
Antibody Secondary Company 
HIF-1α Alexa-555 R & D 
HIf-2α Alexa-555 R & D 
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Table 2.6 Primer pairs used for q-PCR 
Antibody M.W. 
(kDa) 
Secondary Company 
HIF-1α 118 Goat R & D 
HIf-2α 120 Mouse R & D 
pPDH E1-α subunit (Ser293) 43 Rabbit Abcam 
PDH E1-α subunit 43 Mouse Abcam 
PDK1 60 Rabbit Cell Signaling 
LDHa 37 Rabbit Cell Signaling 
p-AMPK (TH172) 62 Rabbit Cell Signaling 
AMPKα 62 Rabbit Cell Signaling 
LC3A/B 14, 16 Rabbit Cell Signaling 
PARP 89, 116 Rabbit Cell Signaling 
Cleaved caspase 3 17, 19 Rabbit Cell Signaling 
mTOR 289 Rabbit Cell Signaling 
p-mTOR (Ser2448) 289 Rabbit Cell Signaling 
p-Akt (TH308) 80 Rabbit Cell Signaling 
p-Akt (Ser473) 80 Rabbit Cell Signaling 
p-p44/p42 MAPK (Erk1/2) 
(TH202/Tyr204) 
44, 42 Rabbit Cell Signaling 
VDAC 31 Goat Santa Cruz 
Α-tubulin 55 Mouse Sigma 
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2.2 METHODS 
2.2.1 Cell Culture 
Rat pheochromocytoma PC12 cells, human colon cancer HCT116 cells and mouse 
embryonic fibroblasts (MEFs) were obtained from American Tissue Culture 
Collections (ATCC, Manassas, VA).  A mutant cell line, HCT116 SCO2-/-, which is 
deficient in synthesis of cytochrome c oxidase SCO2, the assembly unit for complex 
IV of the ETC, were kindly donated by P.  M.  Hwang (NIH).  The HCT116 SCO2-/- cells 
were created using targeting vectors which were delivered by recombinant adeno-
associated virus (Sung et al., 2010).  Both alleles of the SCO2 gene were disrupted in 
the HCT116 cell line creating a homozygous knockout.   
MEF cells were normally cultured in Dulbecco's Modified Eagle's medium (DMEM) 
with 10 % fetal bovine serum (FBS), 10 mM HEPES (pH7.2), 2 mM L-glutamine (L-
Gln), 100 U/ml penicillin /100 µg/ml streptomycin (P/S).  PC12 cells were grown in 
RPMI 1640 medium supplemented with 10 mM HEPES (pH7.2), 2 mM L-Gln, 10% 
horse serum (HS), 5 % FBS and P/S.  Once seeded PC12 cells were grown in RPMI 
medium supplemented with 1 % HS, HEPES (pH7.2), 2 mM L- L-Gln, P/S and 100 
ng/ml nerve growth factor (NGF) and left to differentiated for 5 days prior to the 
start of each experiment (differentiation made PC12 cells into a neuronal cell 
modal.).  HCT116 and HCT116 SCO2-/- cells were grown in McCoys medium 
supplemented with HEPES, L-glutamine, 10% FBS and P/S.  All cells were grown in 
humidified atmosphere of 5 % CO2 and 95 % air at 37
oC unless otherwise stated.   
For experiments in 96 well plates, all wells were coated with 0.01% collagen IV.  
MEF cells were seeded at a density of 4*104 cells /well, PC12 cells were seeded at 
5*104 cells /well, HCT116 and HCT116 SCO2-/- cells were seeded at 2.5-4.0*104 cells 
/well.  For protein isolation of PC12 cells were seeded in a 12 well plates at a 
density of 5*105 PC12 cells / well.  HCT116 cells were seeded in 6 well plates at a 
density of 1.2*105 cells / well at 20.9 % O2 and a density of 3*10
5 when grown 
under 3% O2, HCT116 SCO2
-/- cells were seeded at 2*105 cells / well under 20.9 % 
O2 and 3*10
5 cells / well at 3% O2 (different densities to account for differences in 
growth under different O2 conditions).   For siRNA transfection HCT116 and HCT116 
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SCO2-/- cells were grown at either atmospheric (20.9 %) or hypoxic (3 %) O2 for 3 
days and then seeded on day 4 in 6 well plates.  Cells were then grown in respective 
O2 environments for a further 3 days.  Different seeding densities in different cell 
lines and plates are shown in Table 2.1.   
Working media (WM) was used in metabolic substrate experiments.  It was made 
using reconstituted DMEM powder in Milli-Q water and filter sterilised.  Twelve 
different WM were made using different combinations of 10 mM gucose (Glc), 10 
mM galactose (Gal), 2 mM glutamine (Gln) and 1mM pyruvate (Pyr), all media 
contained 100 nM NGF and all were serum-free.  All but the media used for ECA 
experiments contained 20 mM HEPES (pH 7.2).  WM are show in table 2.2.  The 
medium was replaced at the start of each experiment and the cells grown for 2 
hours.   
2.2.1.1 Fluorescent Microscopy 
For microscopy, PC12 cells were seeded at a density of 2.5*104 cells/ 1cm2 on glass 
bottom Matek mini-dishes with a collagen IV (0.0075) and poly-D-lysine mix coating 
and differentiated for 5 days with NGF.  HCT116 cells were seeded at 1.5*104 cells/ 
dish and HCT116 SCO2-/- cells were seeded at 2.2*104 cells / dish.   
All probes were loaded in serum free OPTIMEM except TMRM and PMPI which 
were maintained in the cells normal media at 20 nM for the duration of the 
experiment.  Transfection was performed using Lipofectamine-2000 and serum free 
OptiMEM medium for Mitocase12 and mtAlpHi.  The probe was diluted to a 
concentration of 5 ng/ml in serum free OPTIMEM, in a separate tube 1 µL 
lipofectamine-200 was added to 40 µl of serum free OPTIMEM.  The tubes were left 
for 5 minutes and then combined.  The combined mixture was left for a further 20 
minutes to allow complexes to form.  In the meantime the cells were washed with 
serum free OPTIMEM 3 times and the media was replaced with serum free 
OPTIMEM (160 µl/dish).  Once probe/lipofectamine complexes had formed the 
solution was added drop-wise onto the dish (40 µl/dish).  The dishes were left for 
10-14 hours and then the media was replaced with normal seeding medium.  
Measurements were then conducted (excitation 488 nm, emission 500-540).    
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To stain cells for cytosolic Ca2+ 2.5 µM Fluo4-AM was used, the probe was diluted in 
serum free OPTIMEM and left for 60 minutes, the cells were then washed with 
normal seeding media 3 times and the left for 30 minutes and measured (excitation 
488 nm, emission 500-540 nm).   The process was the same for JC1 (ΔΨm stain).  To 
assess ΔΨm and ΔΨp, TMRM and PMPI were used (20 nM), staining started 30 
minutes prior to measurement and probes were maintained at 20 nM throughout 
the experiment (excitation 543 nm, emission 555-600 nm).   Staining was conducted 
in normal seeding medium.   
A list of probes, function and excitation and emission wavelengths can be found in 
Table 1.  Microscopy measurements were conducted using an Olympus FV1000 
confocal laser scanning microscope under controlled conditions of CO2, humidity 
and temperature.   In all experiments the differential interference contrast and 
fluorescence images were collected kinetically with a 60× oil immersion objective in 
two planes using 0.5 μm step and 20–30 s intervals. The resulting z-stacked images 
were analysed using FV1000 Viewer software (Olympus), Excel, Adobe Photoshop 
and Illustrator.  The staining details are described in table 2.3.   
Immunofluorescence analysis of PC12 cells was conducted in Ibidi chambers.  Cells 
were washed 3 times with PBS, fixed with 4% paraformaldehyde in PBS for 10 
minutes, then washed 3 times with PBS, quenched with 50 mM NH4Cl/PBS for 15 
minutes.  Cells were then washed with PBS 3 times, permeabilised with 0.25% 
TritonX-100 for 10 minutes, blocked with 5% FBS/PBS for 30 minutes, incubated 
with Novus anti-HIF-1 (1 in 200 dilution) primary made up in 5% FBS/PBS for 50 
minutes.  Cells were washed 5 times with PBS and then incubated with Alexa-
fluorescent 488 conjugated secondary antibodies (1 in 500 dilution) for 50 minutes 
in the dark, and washed 5 times with PBS.  Cells were counterstained with 300 nM 
DAPI for 10 minutes, washed once with PBS, dipped in deionised water and 
mounted with ProLong® Gold and air-dried (Table 2.5). The intensity and 
localisation of HIF-1 was analysed on an Olympus FV1000 confocal laser scanning 
microscope. DAPI and Alexa-488 images were collected with a 60X oil immersion 
objective in eight planes with 0.5 µm steps in sequential mode, using standard 
excitation and emission wavelengths. The resulting single plane (DIC) and z-stacked 
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fluorescent images were analysed using FV1000 Viewer software (Olympus), Adobe 
Photoshop and Illustrator.  Assistance was given with the microscopy from Dr 
Alexander Zhdanov.   
2.2.1.2 siRNA transfection 
Transfection of siRNA was conducted on cells grown in either 6 or 12 well plates.  
Cells were washed with antibiotic and serum free OPTIMEM medium and 
transfected using Lipofectamine-2000 as stated above in 2.2.1.1.  Concentrations of 
10 nM siRNA or control scrambled siRNA were used.  Serum was added 4 hours 
after transfection and media replacement to complete media was done after 
approximately 16 hours.  The cells were then grown for 72 hours and either protein 
or RNA isolated.  For siRNA transfection under hypoxic conditions, cells were placed 
into the hypoxia workstation set to 3% O2 on day 1, cells were then seeded on day 
3, transfection took place on day 4 and isolation of either protein or RNA was 
conducted on day 7, 72 hours post transfection.   
 
2.2.2 Cell Based Assays 
2.2.2.1 Oxygen Consumption Rate (OCR) 
OCR is measured using the phosphorescent O2-sensitive probe, MitoXpress.  Cells 
were grown and treated as stated; media was then replaced with 100 µl of air-
equilibrated medium containing 200 nM MitoXpress probe.  The wells were 
covered in 150 µl pre-warmed mineral oil to provide an O2-impermeable seal.  The 
plate was then quickly read on a TR-F reader Victor 2 (PerkinElmer Life Sciences) 
pre-set at 37oC and measured at 20.9% or 4%  atmospheric O2 (i.e. with TR-F reader 
placed in the hypoxia chamber).  Each sample was measured every 3-5 min for over 
60 min.  Two intensity values were taken at delay times of 30 and 70 µs with a gate 
time of 100 µs.  Intensity signals were converted into phosphorescence lifetime () 
values as follows: τ = (t2-t1)/ln(F1/F2), where F1, F2 are the TR-F intensity signals at 
delay times t1 and t2. Initial rates of cell deoxygenation were calculated as 
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nmole/min per 106 cells.  Average O2 levels were calculated and then OCR was 
calculated O2 consumed by cells in 1 min per 1 mg of total soluble protein.   
2.2.2.2 Extracellular Acidification (ECA) 
Cells were seeded in 96 well plates coated with 0.01 % collagen IV, PC12 cells were 
differentiated for 5 days and MEF, HCT116 and HCT116 SCO2-/- cells were left for 24 
hours after seeding.  Firstly cells were washed with and then replaced with 150 µl 
un-buffered DMEM supplemented with 1 mM sodium pyruvate, 10 mM glucose and 
2 mM L-glutamine (not the case for different substrate work).  Cells were then 
incubated under CO2 free conditions at 37
oC for 2-2.5 hours.  Medium was then 
replaced with buffered DMEM containing 10 mM HEPES, 1 mM sodium pyruvate, 
10 mM glucose and 2 mM L-glutamine and placed back into the CO2 free incubator 
for 30 min – 1 hour.  After a period of at least 3 hours under CO2-free conditions the 
medium was changed to 100 µl buffered DMEM which contained 1 µM pH-Xtra 
probe.  For measurement of lactate-ECA (L-ECA) the plate was then read on a TR-F 
reader Victor 2 (PerkinElmer Life Sciences) pre-set at 37oC and measured at 20.9 %, 
4 % , 3 % or 1 % atmospheric O2.  To measure Total-ECA (T-ECA) a layer of 150 µl of 
pre-warmed to 37oC heavy mineral oil was added to seal the plate after the 
addition of the medium with probe, immediately prior to measurement.   The plate 
was read for at least 1 hour using 340 ± 35 nm excitation and 615 ± 8.5 nm 
emission, two intensity signals were measured at delay times of 100 and 300 µs 
with a measurement window of 30 µs.  Intensity values were converted into probe 
fluorescence life-time (τ) values τ= (t2-t1)/ln(F1/F2), t1 and t2 relate to the two delay 
times and F1 and F2 the intensity signals at those corresponding times, τ is then 
converted into pH and then H+ values .   
2.2.2.3 Intracellular Oxygen (iO2) 
Cells were seeded in 96 well plates coated with 0.01% collagen IV, after 24 hours 
for MEF and HCT116 cells and 4 days of differentiation for PC12 cells, medium 
which contained 10 µg/ml NanO2 probe was added to the cells, cells were then 
incubated for further 16-24 hours at 37ºC. After which cells were washed with 150 
µl medium, then replacement with 300 µl fresh medium was done, and the plate 
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was read on a TR-F reader Victor 2 (PerkinElmer Life Sciences) pre-set at 37oC and 
measured at 20.9 %, 4 % or 3 % atmospheric O2 (i.e. with TR-F reader placed in the 
hypoxia chamber).  Each sample well was measured every 3-5 min over 6 hours, 
taking two intensity readings at delay times of 30 and 70 µs and gate time 100 µs 
(excitation/emission: 340/642 nm). Intensity signals were converted into lifetime 
using the equation above (OCR section).  There is no correction for back diffusion, 
experiments conducted at 21% O2 and 4% O2 are not directly compared so 
corrections for differences in potential back diffusion in various O2 conditions are 
not required.   
2.2.2.4 ATP  
ATP levels were assessed using Promega CellTiter-Glo assay.  Cells were grown on 
96 well plates and treated as stated, equal amounts of CellTiterGlo reagent as 
media in the well was added to each well to lyse the cells.  The plate was then 
shaken for 2 min and each sample was then transferred into a white well plate and 
read on Victor 2 plate reader under standard luminescence settings.  For all 
metabolic assays protein concentrations were assessed using BCA protein assay kit.  
Data was then corrected to protein content for each sample (BCA assay is described 
below in 2.2.3.1).   
2.2.2.5 Nanoparticle Toxicity Testing 
Two sets of nanoparticles (NPs) were assessed, firstly bare molecular imprinted 
polmer (MIP) NPs made up of methacrylic acid (MAA), ethylene glycol 
dimethacrylate (EGDMA), trimethylolpropane trimethacrylate (TRIM), 
pentaerytHitol-tetrakis-(3-mercaptopropionate) (PETMP) and N,N-
Diethyldithiocarbamic acid benzyl ester and then with a poly(ethylene glycol) (PEG) 
methacrylate shell with a molecular weight or either 1100 or 4000 kDa (Poma et al., 
2013, Moczko et al., 2013).  Secondly a group of MIP NPs which dissolved in H2O 
(100 mL) in the presence of 30 g of trypsin-derivatised glass beads and composed of 
39mg N-isopropylacrylammide (NIPAm), 2 mg N,N'-Methylenebisacrylamide ( BIS), 
33 mg N-tert-Butylacrylamide (TBAm) and 2.2 μL Acrylic acid.  These MIP NPs are 
referred to as Tyrpsin NPs, some fluorescent Rhod/Trypsin NPs were made by 
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addition of 1% in mol (compared to the total moles in solution) of 
Methacryloxyethyl thiocarbamoyl rhodamine to the Trypsin NPs.  
 
2.2.3 Protein Isolation and Western Blot analysis 
Cells were seeded in either 12 or 6 well plates.  After treatment cells were placed 
on ice and washed twice with PBS and then lysed with lysis buffer containing 150 
mM NaCl, 1 mM EDTA, 1 % IGEPAL CA-630, 50 mM HEPES (pH = 7.5) phosphatase 
inhibitors and protease inhibitors.  Plates were kept on ice on a shaker for 15 
minutes and then scraped collecting the lysate.  Lysate was centrifuged for 10 min 
at 16,000 g at 4oC.  Protein concentrations were measured by BCA protein assay kit 
and lysates normalised.  Either 8 % or 4-20 % polyacrylamide gel electrophoresis 
was used to separate the proteins, which were then transferred onto a 0.2 µm 
PVDF membrane using a wet mini-transfer system and blocked with either 5 % milk 
/TBST or 5 % BSA/TBST depending on the primary antibody used, for 2 hours at 
room temperature.  Incubation with primary antibodies was conducted in either 5 
% milk /TBST or 5 % BSA/TBST at 4oC overnight and then 2 hours at room 
temperature for horse radish peroxidise conjugated secondary antibodies.  
Visualisation of the blots was done using ECL prime reagents using a LAS-3000 
imager (FujiFilm) with Image Reader LAS-3000 2.2 software.  Data was analysed 
quantitatively using Image J software, normalising signals to α-tubulin.  Images 
were processed using Picasa, Photoshop and Illustrator programs.  A list of 
antibodies used for Western blotting can be found in Table 2.4.   
 
2.2.4 BCA Protein Assay 
Prior to preparation of lysates for Western blot, protein concentrations were 
quantified using the Thermo Fisher Scientific BCA Protein Assay Kit, as per 
manufactures instructions.  Protein concentrations were tested along with a range 
of standards, a working reagent was added and the plate incubated at 3 oC for 30 
min, absorbance was then measured at 562 nm. Protein concentrations were 
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calculated from the standard curve and concentrations normalised to the same 
level.  Protein concentrations were also obtained from iO2, oxygen consumption 
rate and extracellular acidification experiments and the data normalised according 
to concentrations.   
 
2.2.5 RNA Isolation and Reverse Transcription and q-PCR 
RNA was isolated using Macherey Nagel/ Fisher NucleoSpin RNA II kit.  Cells were 
washed with PBS and then isolated according to kit guidelines.   
Reverse transcription (RT) was completed using a Promega kit as per manufactures 
protocol.  Briefly, RNA was diluted to 1.5 µg in Nuclease-free water and 0.5 µg 
oligo(dT)15 primers added, tubes were then incubated at 70 
oC for 5 min followed by 
5 min on ice.  An RT buffer containing, 2 mM MgCl2, 0.5 mM dNTP, 1 unit RNase 
inhibitor and 160 units reverse transcriptase was added to the RNA and incubated 
at 42 oC for 1 hour.  The reverse transcriptase was then heat inactivated by 
incubating the tubes at 70oC for 15 min.  A negative control without RNA added was 
also done.   
Real-Time PCR experiments were conducted using the Maxima SYBR green/qPCR 
Master Mix kit.  Each well contained; 150 ng cDNA, 0.325 µM of forward and 
reverse Primer, 10 µl Maxima SYBR Green qPCR Master Mix (2x), 0.5 µM ROX and 
made up to 20 µl with nuclease-free water.  Real-time PCR was then performed on 
an Applied Biosystems 7300 Real Time PCR System using the following settings; 
stage 1, 10 min at 95 oC, stage 2, 45 cycles of; 95 oC for 15 sec denaturation, 60 oC 
for 20 sec annealing and 72 oC for 28 sec extension.  A total sample volume of 20 µl 
was used with primer concentration of 0.325 µM.  A list of primers used for q-PCR 
can be found in Table 2.5.    
2.2.6 Statistical Analysis 
Statistical analysis was performed using the results of 3–6 independent 
experiments using the programs, Excel and Minitab.  Confidence levels of 0.05, 0.01 
and 0.001 were deemed as statistically significant.  The differences between mean 
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values were assessed by 2-tailed Student t-test once equality of variance among 
samples were checked by the Levene’s test.  The differences in iO2, TMRM, 
Mitochondrial Ca2+ (in Δ%) were evaluated using Mann–Whitney U-test.  To ensure 
accurate data, the majority of the experiments were performed in 3–8 replicates, 
and repeated at least 3 times. The ECA, OCR, iO2 and ATP levels were normalised to 
the total protein content in the samples.  Fluorescence intensities on the confocal 
images (TMRM, mitoCase12, Fluo4) were examined in kinetic mode analysing 5–20 
cells in 3 independent experiments.  The differences between the mean values 
were evaluated using two-tailed Student t-test.   q-PCR data was normalised to β-
actin levels and corrected to normoxic WT control, averages were made of at least 
3 separate experiments.  Western blots were quantified using ImageJ and 
normalised to α-tubulin levels.  If phosphorylated proteins were measured these 
were normalised to total protein level of the corresponding protein.    
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CHAPTER 3.  APPLICATION OF CELL ENERGY BUDGET PLATFORM 
IN TOXICOLOGICAL AND METABOLIC STUDIES WITH CELL MODELS 
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3.1 ABSTRACT 
The cell energy budget system can determine the contributions of the main 
metabolic pathways of oxidative phosphorylation, Krebs cycle and glycolysis to ATP 
production using O2 and pH sensitive probes.  Glycolysis, glutaminolysis, the Krebs 
cycle and oxidative phosphorylation are the main contributors to cell metabolism. 
Glycolysis and glutaminolysis are strongly elevated in cancer cells, providing them 
with ATP and building materials for tumour expansion.  As a result, cancer cells can 
actively proliferate at deep hypoxia and often have elevated hypoxia inducible 
factor 2 (HIF-2) levels.  However, in energy stress conditions HIF pathways and 
viability of cancer cells may be suppressed by deficiencies in metabolic pathways, 
and this can be probed by depriving the cells of key metabolic substrates.  We 
examined the contribution of key metabolic substrates (glucose, pyruvate or 
glutamine - 12 combinations in total) to stress conditions, mitochondrial uncoupling 
with FCCP, or hypoxia (4 % O2). The cells maintained on at least one of the 
substrates did not lose viability, mitochondrial Ca2+, membrane potential or 
respiration.  Upon uncoupling with FCCP the mitochondria were depolarised 
similarly in all the cases, but a strong increase in respiration was only seen in the 
cells fed on glutamine combined with either glucose or pyruvate.  Surprisingly, the 
response to FCCP did not correlate with ATP levels, which rapidly dropped upon 
uncoupling in the absence of glucose.  Inhibition of glutaminolysis resulted in a 
reversal of the glutamine dependant effect.  At reduced O2 availability (4 % and 0 % 
of atmospheric O2), cell bioenergetics and local oxygenation varied drastically 
depending on the substrate composition.  Cellular ATP and O2 levels, orchestrated 
HIF-2α stabilisation. At 4 % O2, rapid and deep deoxygenation was observed in the 
cells lacking glycolytic ATP and maintained on glutamine and pyruvate.  In these 
cells HIF-2α levels reached maximum in 3 H and then gradually decreased.  At the 
same atmospheric O2, only minor HIF-2α stabilisation was seen in the cells fed on 
glucose and/or pyruvate.  These results indicate that inhibition of key metabolic 
pathways (e.g. glutaminolysis) can modulate HIF regulatory pathways, metabolic 
responses and survival of cancer cells in hypoxia or upon activation of respiration. 
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3.2 INTRODUCTION 
3.2.1 The Cell Energy Budget (CEB) platform 
The CEB system can determine the contributions of the main metabolic pathways of 
OxPhos, Krebs cycle and glycolysis to ATP production.  The platform uses O2 and pH 
sensitive probes to assess the different metabolic pathways, as described in Ch. 1 
(1.4.2) and (Hynes et al., 2009a, O'Riordan et al., 2007, Zhdanov et al., 2011b).   
Toxicity testing is of vital importance for any potential therapeutic agent, there are 
many drugs that are known to cause mitochondrial toxicity, including some 
chemotherapeutic agents, antibiotics and antiretroviral drugs.  Drug-induced 
mitochondrial toxicity can occur by; inhibition of ETC complexes (antipsychotics or 
local anaesthetics), ROS generation (doxorubicin), disruption to mitochondrial 
protein synthesis and biogenesis (antivirals) or uncoupling reagents such as non-
steroidal anti-inflammatory drugs (Chan et al., 2005).   
It is important to assess mitochondrial toxicity, which has been shown to cause 
organ toxicity.  The antiretroviral drugs, nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs) used in AIDS treatment prevent normal reverse 
transcription, interfering with mitochondrial replication, which can lead to 
decreased mitochondrial function within tissues and can cause myopathy, 
peripheral neuropathy and lactic acidosis (Walker et al., 2002, Wang and Flint, 
2013).  Mitochondrial toxicity can go undetected using tradition methods such as 
ATP, MTT and LDH assays.  These assays only work to test cell viability; a compound 
may In fact be toxic but not lead to apoptosis or necrosis.  Mitochondrial toxicity is 
one of the causes of late stage drug attrition in the pharmaceutical industry, so 
methods to assess this characteristic at an early stage of drug development are very 
important (Zhang et al., 2009).   
Both within our lab and outside, it has been shown that the CEB platform can be 
used to assess mitochondrial toxicity in both eukaryotic cells and bacteria (Hynes et 
al., 2006, Jasionek et al., 2010, Bansal et al., 2013, Beeson et al., 2010).   
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Each metabolic pathway has some spare capacity, so in times where there is 
decreased O2 for example, OXPHOS would be reduced but glycolytic activity would 
increase as a compensatory measure to maintain constant ATP levels. In a cell 
energy budget platform, assays which are performed are more sensitive and more 
selective than standard viability assays.  A panel of molecular imprinter polymeric 
(MIPs) nanoparticles (NPs) imprinted with melamine were previously tested, using 
MTT assay and found to have no toxic effect (Supplemental 1).  Here we performed 
a more detailed metabolic analysis of the same panel of NP using the CEB system.   
The CEB can also be used to study metabolic changes in cells supplied with different 
metabolic substrates under differing stress conditions.  It is known that cancer cells 
have high levels of glycolysis and glutaminolysis consuming glucose and glutamine 
respectively.  When there are shortages in metabolic substrates from hypoxia, 
pharmacological treatment or metabolic disorders, certain cell responses ensue 
which could be fatal for cancer cells.  It is known that different metabolic substrates 
enter different metabolic pathways.  The cell energy budget system is able to 
distinguish differences in metabolic substrates utilisation in different metabolic 
pathways.  Glucose is the main metabolic fuel for glycolysis, in which one molecule 
can be converted into two pyruvate molecules, which then can be fed into the 
Krebs cycle after conversion to acetyl-CoA.  When glucose is replaced with 
galactose there is no net gain of ATP produced from glycolysis, due to the 
significantly slower rate of conversion into glucose-6-phophate compared to that 
from glucose, and there is a compensatory increase in OXPHOS as a result 
(Marroquin et al., 2007, Rossignol et al., 2004).  Glucose deprivation in PC12 cells 
has been shown to decrease ATP levels, increase reactive O2 species (ROS), 
decrease mitochondrial membrane potential (∆Ψm) and lead to both apoptosis and 
necrosis after 24 H (Liu et al., 2003).  It has been shown that there may be an 
increase in glucose metabolism in response to increased ROS from decreased 
OXPHOS activity in cancer cells (Aykin-Burns et al., 2009).   
Another important metabolic substrate is glutamine, which can be converted into 
glutamate and then α-ketoglutarate (α-KG) via glutaminolysis, and utilised into the 
Krebs cycle.   Cancer cells are considered to be addicted to glutamine, which 
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provides the cells with all non-essential amino acids, nitrogen for lipid and 
nucleotide biosynthesis, activates the TORC1 signalling, as well as being a 
mitochondrial substrate utilised in the Krebs cycle (Wise and Thompson, 2010).  The 
high level of glutaminolysis in cancer cells has been exploited as a possible research 
area for cancer therapeutics.  Studies include; inhibition of glutamine uptake by 
blocking transporters, inhibiting complex I to prevent NAD+ generation required for 
glutamine utilisation, lowering blood glutamine levels and inhibiting glutamine 
dependent mTOR activation (Avramis and Panosyan, 2005, Esslinger et al., 2005, 
Krause et al., 2002). 
Metabolic substrates play important roles in cancer cells during hypoxia, high levels 
of glycolysis and glutaminolysis are important for cell survival.  Glutamine and 
glucose are important in HIF-signalling during hypoxia, deprivation of one or both of 
these substrates can lead to inhibition of HIF-1α accumulation under hypoxic 
conditions (Kwon and Lee, 2005).  Under glucose and oxygen deprivation, down-
regulation of HIF signalling occurs as a result of depleted ATP levels, causing 
disruption of translational processes (Zhdanov et al., 2013).  Increased expression 
of HIF-2α is observed in PC12 cells, and is strongly associated with development of 
pheochromocytoma (Span et al., 2011).   
Using rat pheochromocytoma PC12 cells and other cell lines, we studied how the 
availability and utilisation of major metabolic substrates (glucose, glutamine, and 
pyruvate) modulate the respiratory response of cancer cells to mitochondrial 
uncoupling.  We also studied different factors involves in HIFα accumulation, 
including the availability of key metabolic substrates, OCR, iO2, hypoxic stress, 
activation of AMPK, Akt and Erk, cellular ATP levels and transcription of HIF-α and 
PHD.  
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3.2.2 Aims 
Using the CEB platform to perform mitochondrial toxicity testing and to investigate 
the contribution of key metabolites (e.g. glucose, pyruvate, and glutamine) to: 
1. Cell bioenergetics and responses to uncoupling. 
2. To study the factors involved in HIF-α accumulation. 
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3.3 RESULTS 
3.3.1 Toxicity Testing of Nanoparticle Preparations 
Toxicity levels of bare and PEG-1100 and PEG-4400 coated NPs were assessed by 
the CEB platform in MEF cells.  Our results show that there was no difference to 
total ATP levels observed after 24 and 48 hour NP exposure to MEF cells (Fig. 3.1C).  
Next, intracellular O2 levels were measured, there was no difference observed 
between the MIP NP exposed cells and the control (Fig. 3.1A-B).  However, 
differences in oxygen consumption rate were seen (Fig. 3.1E-F).  There were no OCR 
changes in the cells exposed to bare MIP NPs compared to control treated with 
deionised water, which the NPs were made up in.  But there was a decrease in OCR 
in the PEGylated MIP NPs treated MEFs.  A reduction of almost 60% in OCR was 
found in the MIP NPs coated with PEG1100, and a 30% reduction in the MEFs 
treated with MIP NPs coated with PEG4000, these changes remained relatively 
constant after 48 H exposure (p<0.001 for both time points) (Fig. 3.1F).  Lactate-
extracellular acidification (L-ECA) assay revealed an induction in glycolysis in the 
PEG1100 MIP NP treated cells, shown by a 40% increase in L-ECA after 24 hour 
exposure.  No change was observed in the Bare or the PEG 4000 MIP NPs (Fig. 
3.1D).   
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Figure 3.1.  Toxicological analysis of Bare and PEG-1100/-4000 NP 
preparations.  MEF cells were exposed to either Bare or PEG-1100/-4000 NPs for 
up to 48 hours, NPs were suspended in sterile water, which was used as a control.  
Results were normalised to control.  CEB analysis; iO2 profiles after (A)  24 hours and 
(B) 48 hours, (C) ATP values after 24 H, (D)  L-ECA after 24 hours show increased 
glycolytic rate in PEG1100 NP treated cells and (E) OCR after 24 hours and (F) after 
48 hours show decreased oxygen consumption in PEG1100 NP exposed cells. ATP, 
OCR and ECA were normalised to control (sterile water), all data were n=3 with 
error bars showing standard deviation.   
 
Toxicity studies were also performed on another set of MIP NPs, Trypsin and 
Rhod/trypsin in MEF cells (Fig. 3.2).   ATP and iO2 were unaffected in MEF cells 
which had undergone up to 48 H incubation with either Trypsin or Rhod/trypsin NPs 
(Fig. 3.2A-C).  However there was a significant reduction in OCR of 55% and 56% 
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from control in cells treated with Trypsin and Rhod/trypsin NPs for 24 h respectively 
(Fig. 3.2E).   This reduced OCR was maintained for at least 48 H exposure (Fig. 3.1F).  
A substantial increase in ECA was observed in cells exposed to trypsin NPs (44%), 
while a 17% increase was seen in Rhod/trypsin treated cells (Fig. 3.2D).  This is 
indicative of mitochondrial toxicity; the mitochondria appear to not be fully 
functioning and so OXPHOS capacity has decreased and glycolysis increased to 
allow steady ATP levels to be maintained. 
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Figure 3.2.  Toxicological analysis of Trypsin or RHOD/Trypsin 
preparations.  MEF cells were exposed to either Trypsin or RHOD/Trypsin NPs for 
up to 48 hours, NPs were suspended in sterile water, which was used as a control.  
Results were normalised to control.  CEB analysis; iO2 profiles after (A)  24 hours and 
(B) 48 H, (C) ATP values, (D)  L-ECA show increased glycolysis in Trypsin NPs and (E) 
OCR after 24 H and (F) after 48 hours decreased O2 consumption in both treatments.  
ATP, OCR and ECA were normalised to control (sterile water), all data were n=3 with 
error bars showing standard deviation.   
 
 
74 
 
The dramatic decrease in OCR in PEG-1100 treated cells and both Trypsin and 
Rhod/trypsin treated cells shows a reduction in the level of respiration in these cells 
(Fig. 3.1E-F and Fig. 3.2E-F).  Together with the increase in L-ECA (Fig. 3.1D and Fig. 
3.2D) in cells exposed to PEG-1100, Trypsin or Rhod/trypsin, showing increased 
levels of glycolysis in these cells to compensate for reduced OXPHOS activity, this 
suggests a significant level of mitochondrial toxicity as a result of exposure to these 
NPs, altering cell metabolism but not inducing cell death.  
These results demonstrate that metabolic OCR and ECA assays offer a more 
sensitive in-depth metabolic analysis for toxicity assessment and can provide 
mechanistic information about mode of action of NP preparations and their targets 
within the cell.  In contrast, conventional (non-specific) tests such as total ATP, LDH 
release and MTT assay, often miss pronounced toxic effects, especially if these are 
masked by compensatory pathways in the cell.  This was the case with our samples.  
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3.3.2 Metabolic Substrates in Cell Bioenergetics 
Oxygen sensitive probes were used to assess respiration and OXPHOS rates.  The pH 
sensitive probe pH-Xtra probe was used to measure extracellular acidification, and 
ATP levels were quantified using a standard luminescent cell viability kit.  The cell 
oxygenation measured using an extracellular O2 probe, MitoXpress-Xtra, is inversely 
related to the respiratory activity in cells.  The degree of the response can be seen 
by measuring intracellular O2 levels using an intracellular phosphorescent O2 probe, 
MitoXpress-Intra (Fercher et al., 2011, Dmitriev et al., 2012).   Extracellular 
acidification can be assessed with the use of a long decay pH- sensitive lanthanide 
probe, pH-Xtra (Hynes et al., 2009a, Zhdanov et al., 2011b).  Experiments were 
conducted as stated in Chapter 2 methods.   
Working media (WM) was used in metabolic substrate experiments.  It was made 
using reconstituted DMEM powder in Milli-Q water and filter sterilised.  Twelve 
different WM were made using different combinations of 10 mM gucose (Glc), 10 
mM galactose (Gal), 2 mM glutamine (Gln) and 1mM pyruvate (Pyr).  All media 
contained 100 nM NGF, and all were serum-free.  All but the media used for ECA 
experiments contained 20 mM HEPES (pH 7.2).  WM are show in table 2.2.  The 
medium was replaced at the start of each experiment and the cells grown for 2 
hours.   
Using rat pheochromocytoma PC12 cells, mouse embryonic fibroblasts (MEF) and 
human colon cancer HCT116 cells, how the availability and utilisation of major 
metabolic substrates (glucose, glutamine, and pyruvate) modulate the respiratory 
response of cancer cells to mitochondrial uncoupling was studied.  This is of 
importance as it has been shown that various cancer cells exhibit altered 
metabolism and mitochondrial function.  Certain pharmacological agents are known 
to cause mitochondrial uncoupling, so the effect of substrate deprivation under 
these conditions is of particular relevance to those studying anti-cancer 
therapeutics.  Cells were incubated with one of the 12 different WM for 2 hours, 
allowing time for metabolic adaptation and then treated with 1 µM FCCP, a 
concentration which had previously been optimised in complete media (Zhdanov et 
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al., 2010b).  The concentration of FCCP was not optimised for each condition and 
extreme treatments such as without any metabolic substrates of just Gal may cause 
PC12 cells to be stressed prior to uncoupling.  However there is a broad 
concentration range which PC12 cells can withstand. 
Firstly, the respiratory responses of PC12 cells to mitochondrial uncoupling were 
studied using the intracellular O2 probe, MitoXpress-Intra, and extracellular O2 
probe MitoXpress-Xtra (Fercher et al., 2011, Dmitriev et al., 2012).  It is known that 
cell oxygenation is inversely related to respiratory activity.  Basal OCR data show 
cells incubated with WM containing Pyr/Gln with or without Gln had the highest O2 
consumption rates, with iO2 values of 93 and 96 µM O2 respectively (Fig. 3.3A).  
Cells supplied with WM containing, Glc, Gal or no substrates had the lowest OCR, 
with values of 127, 136 and 144 µM O2 cells respectively.  Intracellular O2 levels 
upon uncoupling were then investigated, as these indicate the magnitude of 
respiratory response.   Intracellular O2 (iO2) results showed four distinct types of 
profiles (Fig. 3.3B).   
The first type of response was in cells supplied with Gln with either Glc or Pyr, 
which showed a rapid decrease in iO2 followed by continuous, for over an hour, cell 
deoxygenation in response to uncoupling, suggesting an increase in mitochondrial 
respiration.  There was a substantial ∆iO2 in cells which had shown both high 
(Gal/Pyr/Gln and Pyr/Gln) and moderate (Glc/Gln, Glc/Pyr/Gln) basal OCR.  The 
second type of response refers to cells supplied with Pyr or Gln with or without Gal 
and Gal/Gln.  In these cells there was an inhibition of respiration and cell 
reoxygenation.  It was unexpected to see decreased respiration in Gal/Gln supplied 
cells as they had a high level of basal OCR.  The third type of response showed a 
rapid transient decrease in iO2 followed by steady minor cell deoxygenation, 
observed in cells supplied with Glc/Pyr.  iO2 were partially restored but remained at 
this level for up to an hour (Fig. 3.3B).  The fourth type of response displayed no 
change, or a slow progressive reoxygenation, seen in cells supplied with Gal or no 
substrates.   
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The levels of iO2 were plotted at the time points 10 and 60 min after FCCP addition 
(Fig. 3.3C).  A dramatic response was seen in the cells in WM containing Gln in 
combination with either Pyr or Glc.  These cells had a sustained increased 
respiratory rate for at least 60 min, while other cells grown in Glc/Pyr or Glc, for 
instance, showed a slight increase in respiration after 10 min which was absent at 
the 60 min time point (Fig. 3.3C).   
It was observed that after 4 hours of FCCP treatment partial detachment of cells 
from the collagen coated surface of the wells occurred.  To investigate whether the 
decrease in respiration observed in cells supplied with Gal/Gln or Gln was as a 
result of apoptosis, poly (ADP-ribose) polymerase (PARP) levels were studied.  
Cleaved PARP levels are known to increase in cells undergoing apoptosis in order to 
try and repair damaged DNA (Li et al., 2002).  PARP is cleaved after 4 hours FCCP 
treatment in these cells along with a decrease in the 1A/1B-light chain 3 (LC3) I/II 
ratio indicating autophagy occurred (Fig. 3.3D).   
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Figure 3.3.  Differential metabolic response according to substrate 
composition.  PC12 cells were incubated in different WM for 2 hours prior to 
experiment start.   A.  Basel OCR levels (numbers above bars oxygenation values).  
B.  Intracellular O2 profiles were measured using the lifetime values obtained using 
the MitoXpress-Intra probe, uncoupling was achieved by addition of 1 µM FCCP 
after baseline had been established.  C.  The iO2 levels obtained (representative plots 
shown in (B)) were used at the time points 10 and 60 min after FCCP addition were 
plotted.  Deep sustained deoxygenation was observed in cells supplied with Gln in 
combination with Pyr or Glc.  D.  Markers or apoptosis (poly (ADP-ribose) 
polymerase (PARP)) and autophagy (1A/1B-light chain 3 (LC3) I/II ratio (numbers 
above bars)) were studied by western blotting analysis.  Results demonstrate 
moderate increase in the levels of autophagy (PARP is cleaved) in cells supplied with 
Gal/Gln after 4 hours of FCCP treatment * (p < 0.001).  α-tubulin protein bands were 
used for normalisation.  Error bars show standard deviation n=6 (A-C) and 3(D).   
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There are differential O2 consumption rates dependent on substrate composition.  
In cells supplied with Glc, the basal OCR and the responses to FCCP were similar in 
Glc alone and Glc/Pyr (Fig. 3.4A).  There were different profiles observed in cells 
supplied with Glc/Gln, Glc/Gln/Pyr or Gal/Gln/Pyr with steeper deoxygenation in 
coupled cells which showed a rapid decease in O2 levels upon uncoupling.  Cells in 
WM containing no substrates or Gal alone demonstrated similar patterns in 
deoxygenation, in cells with coupled mitochondrial O2 levels decreased slightly and 
then gradually increased, FCCP caused a small decrease (Fig. 3.4B-C).  In Gal/Gln, 
Gal/Pyr and Pyr cells O2 levels were similar to those in Glc/Pyr; however when the 
cells were treated with 1 µM FCCP O2 levels began to rise after approximately 25-30 
min.  In cells supplied with just Gln upon uncoupling there was no change in O2 
levels (Fig. 3.4C). 
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Figure 3.4.  Differential O2 consumption according to substrate composition 
in resting and uncoupled PC12 cells.  PC12 cells were pre-incubated with 
different metabolic substrates for 2 hours and then OCR was measured with or 
without 1 µM FCCP addition.  A.  Showing basal and uncoupled OCR for cells grown 
in WM containing Glc, deep sustained deoxygenation is observed in cells supplied 
with Glc/Gln and Glc/Gln/Pyr upon uncoupling.  B.  Cells with WM containing Gal, 
an inhibition of respiration was observed in uncoupled Gal/Gln cells.  C. Cells with 
WM containing no sugar, no change or progressive reoxygenation can be seen in (-) 
uncoupled cells.   
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In order to elucidate whether this difference in cellular deoxygenation was in part 
due to differences in energy supply, ATP levels were assessed (Fig. 3.5A).  Basal ATP 
levels were constant in all but Gal and no substrate WM treated cells.  However, 
upon FCCP stimulation there was a reduction in ATP in all cells grown in WM which 
did not contain Glc, indicating the importance of the up-regulation of glycolysis to 
sustain constant ATP levels upon uncoupling (Fig. 3.5B).  To distinguish possible 
differences between WM containing Glc, ECA was monitored (Fig. 3.5C).  Very 
limited ECA was observed in cells without Glc.  Resting ECA levels were lower in 
cells supplied with Glc/Pyr/Gln which also had one of the highest basal OCR and the 
highest ECA was seen in Glc/Gln which had the lowest resting OCR; showing that 
glycolytic activity was inversely related to OCR (Fig. 3.3A and Fig. 3.5C).  Increases in 
ECA upon FCCP stimulation occurred in cells given Glc/Gln with or without Pyr, 
which produced a strong sustained respiratory response to FCCP (Fig. 3.3C).   
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Figure 3.5.  Substrate composition dictates ATP levels after uncoupling by 
FCCP in PC12 cells.   A.  Basel ATP levels were measured after 3 hours incubation 
with WM.  A reduction is observed in ATP level in Gal or (-) treated cells.   B.  ATP 
ratio of uncoupled/resting cells.  Bars correspond to 10 min time point and 
numbers 60 min after FCCP addition, all cells without Glc had a dramatic decrease 
in ATP upon uncoupling.  C.  Lactate-extracellular acidification (L-ECA) in resting 
and uncoupled cells.  L-ECA is increased upon uncoupling in cells which showed 
the greatest respiratory response (Glc/Gln with and without Pyr).   Error bars 
represent standard deviation, n=4, * - (p < 0.001).   
 
The effect of substrate composition to ∆Ψp upon uncoupling was assessed using 
PMPI staining.  No effect was seen with FCCP treatment, as a positive control cells 
were treated with 100 mM KCl (Fig. 3.6A-B).   
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Figure 3.6.  The effect of substrate composition on ∆Ψp in PC12 cells.  PC12 
cells incubated with different metabolic substrates were stained with 20 nM PMPI 
(ΔΨp stain) for 30 minutes and then measured; PMPI was maintained at 20 nM 
throughout the experiment.  A. Representative images of ∆Ψp shown of PC12 cells 
stained with PMPI with addition of 1 µM FCCP (no effect observed) or 100 mM KCl 
(positive control).  B.  Staining occurred in a similar manner in all but Gal or no 
substrates, no changes in ∆Ψp were shown in PC12 cells with PMPI staining upon 
uncoupling with 1 µM FCCP, positive control of 100 mM KCl.   
 
Mitochondrial Ca2+ levels and ∆Ψm were investigated, in an attempt to elucidate the 
reason behind the large, sustained increase in respiration in cells in WM containing 
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Gln in combination with either Pyr or Glc.  Increases in mitochondrial Ca2+ are 
known to activate metabolism by activating key metabolic dehydrogenases 
(Denton, 2009).  There was no change in basal ∆Ψm or Ca
2+ levels, except cells in 
WM consisting of just Gal or no substrates (Fig. 3.7A-C).  All cells responded to FCCP 
treatment in a similar manner, with a decreased ∆Ψm (Fig. 3.7A-B) and decrease in 
mitochondrial Ca2+ levels (Fig. 3.7B-C).  The plasma membrane was not affected by 
FCCP; however cells with no metabolic substrates had a substantially depolarised 
∆Ψp at rest.   
In times of energy depletion or when there are changes in intracellular O2, 
metabolic pathways can be activated; hence key metabolic markers involved in 
hypoxia and energy maintenance were investigated after 4 hours of FCCP treatment 
(Fig. 3.7D).   Phosphorylation at Ser2448 of mTOR, a crucial element of cell growth 
and survival, decreased in all cells supplied with Glc upon FCCP addition and 
remained the same in cells supplied with Gal/Gln/Pyr compared with basal levels.  
Phosphorylation of AMPK (TH172), a master metabolic regulator responding to 
changes in the AMP/ATP ratio was decreased slightly in all cells after FCCP 
treatment (Fig. 3.7D).  FCCP strongly affected the Erk pathway decreasing levels of p 
44 Erk (TH 202) / p 42 Erk (Tyr 204) ratios in all cells except those fed with 
Gal/Gln/Pyr.  The same pattern was observed with p-Akt (Ser471) levels.  
Phosphorylation of Erk1/2 (p-44/p-42) and Akt increased in cells supplied with 
Gal/Pyr/Gln.  Cells given Gal/Gln did not show any phosphorylation of p-AMPK, 
Erk1/2 or p-Akt (Fig. 3.7D).   
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Figure 3.7.  The effect of substrate composition on ∆Ψm and mitochondrial Ca
2 
in PC12 cells.  A. Basel ∆Ψm shown by TMRM staining; only cells supplied with no 
substrates or Gal alone had a decreased ∆Ψm.   B.  Representative microscopy 
images of cells stained with 20 nM TMRM (∆Ψm) or 5 ng/ml mitocase12 
(mitochondrial Ca2+) which were dissipated after 1 µM FCCP addition, in a similar 
manner in all WM except no substrates or Gal.  Bar represents 50 µm.  C.  TMRM 
intensity upon 1 µM FCCP decreased to a similar level in all WM within 6 min, except 
no substrates and Gal.  D.  Western blotting analysis of phosphorylation of 
mTOR(Ser2448), AMPKα(TH172), p44 Erk(TH202), p42 Erk(Tyr204) and Akt(Ser473) 
upon 1 µM FCCP treatment for 4 hours.  Data is quantified in bar chart, protein 
phosphorylation levels were normalised to α-tubulin.  Error bars show standard 
deviation of the probe intensities within a cell population (60-80 cells in total), n = 4, 
* p < 0.05 A. compared to Glc/Gln/Pyr, D. FCCP treated compared to non-treated.   
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We observed a prominent role of Gln in FCCP mediated respiratory responses; it is 
known that PC12 cells are highly glutaminolytic (Fig. 3.3B, table 3.1).  In order to 
investigate whether there was a role of glutaminolysis in the respiratory response 
kidney type glutaminase 1 (GLS1) was inhibited using the 10 µM Bis-2-(5-
phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) with 1 hour treatment 
prior to, as well as being maintained in the WM during experiments.  No major 
effect on ATP levels was observed in BPTES treated cells (Table 3.1).  Treatment of 
cells with 10 µM BPTES lead to minimal differences in resting OCR and iO2 levels.   
Addition of BPTES in uncoupled cells dissipated the sustained respiratory ‘first type’ 
response previously observed in cells grown in WM containing Gln in combination 
with either Pyr or Glc (Fig. 3.8A-C).  No effect of BPTES was seen in cells in WM 
which did not contain Gln, showing the specificity of BPTES (Fig. 3.8C). The iO2 
profile observed in cells supplied with Gal/Pyr/Gln or Pyr/Gln changed from a type 1 
to a type 2 respiratory response, with reoxygenation such as that seen in cells fed 
with Gal/Pyr or Pyr (Fig. 3.8A).  GLS1 inhibition increased glycolytic activity in cells 
supplied with Glc/Pyr/Gln and Glc/Gln (2.6 fold and 1.5 fold respectively); which 
suggests a substantial induction in glycolysis (Fig. 3.8D).  BPTES treatment did not 
change L-ECA after FCCP stimulation (Fig. 3.8D).   
Table 3.1 Effect of GLS inhibition on ATP levels in PC12 cells at rest and 
uncoupled 
WM and 
treatment 
Glc/Pyr/ 
Gln 
Glc/Pyr Glc/Gln Glc Gal/Pyr/ 
Gln 
Gal/Gln Pyr/Gln Gln 
Resting 0.99 1.04 1.04 1.02 1.06 0.89 0.95 0.88 
Uncoupled 1.07 1.11 1.04 1.14 0.78 0.56 0.37 0.43 
Averaged BPTES (+) ATP and averaged BPTES (-) ATP were calculated, BPTES 
(+)/BPTES (-) ratio then determined, data shown in arbitrary units [a.u.].  
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Figure 3.8.  Inhibition of GLS1 changes respiratory response in cells supplied 
with Gln containing WM.   PC12 Cells were incubated with different metabolic 
substrates for 2 hours prior to the start of each experiment.  A. iO2 profiles with 
GLS1 inhibitor 10 µM BPTES or mock control DMSO.   B.  Changes in iO2 at 10 and 
60 minute time points, when glutaminolysis is inhibited the sustained deep 
deoxygenation response is reversed, and iO2 increases.  C.  OCR plots for cells 
supplied with Gal/Pyr/Gln or Glc/Pyr with and without 1 µM FCCP and 10 µM 
BPTES, the change in respiratory response to FCCP is only observed in cells 
supplied with Gln in the WM demonstrating BPTES selectivity for GLS1, the 
response is also only seen in uncoupled cells.  D.  L-ECA BPTES/DMSO treatment.  
Error bars show standard deviation (n=4).  * - (p < 0.01).   
 
To see if this effect was specific for PC12 cells or cancer cells, a further two cells 
lines were tested, human colon cancer cells (HCT116) and the non-cancerous 
mouse embryonic fibroblasts (MEFs).  In HCT116 the pattern of deoxygenation 
upon uncoupling with FCCP was similar to that in the PC12 cells, with a less 
prominent effect (Fig. 3.9A). The largest decrease upon FCCP treatment occurred in 
cells supplied with Gln with either Pyr or Glc with or without Gal (Fig. 3.9C).  As 
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observed in PC12 cells, HCT116 cells were unable to withstand FCCP treatment 
when supplied with Gln or Gal/Gln (Fig. 3.9A).  These cells had low iO2 levels at rest 
with an increase in iO2 levels with FCCP treatment.  BPTES treatment in HCT116 
cells resulted in reduction in iO2 in all cells in WM containing Gln, supressing the 
previously FCCP induced sustained increase in respiration, however the responses 
were not as strong as those observed in PC12 cells, suggesting HCT116 cells are less 
sensitive to BPTES treatment (Fig. 3.9A).    
In MEFs the response to FCCP was generally more rapid and transient and even in 
the absence of Gln, MEF cells were still able to generate a continuous and positive 
response to FCCP (Fig. 3.9B).  The type of responses seen in MEF cells differed to 
that seen in the other two cell lines with iO2 profiles being either: 
The first response was characterised by a rapid increase in respiration followed by 
partial or complete restoration of resting iO2 (Gln with Glc or Pyr as well as Glc/Pyr) 
(Fig. 3.9B).   The second response showed a decrease in respiration and cell 
reoxygenation (no substrates, Gln and Pyr alone or with Gal).   Lastly, the third 
response displayed no significant changes in respiration and iO2 (Glc or Gal alone).  
The greatest response to uncoupling in MEF cells was from those supplied with 
Glc/Pyr/Gln; in these cells GLS1 inhibition was only able to blunt the response to 
uncoupling.   In the absence of Gln, MEFs were able to give a sustained positive 
response to FCCP, as seen in cells supplied with Glc/Pyr (Fig. 3.9B-C).   
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Figure 3.9.  Inhibition of GLS1 changes respiratory response in cells supplied 
with Gln containing upon uncoupling in HCT116 and MEF cells.  A.   iO2 
profiles for iO2 profiles upon uncoupling in HCT116 cells, a similar pattern of 
respiratory response to uncoupling is observed in these cells as was seen in PC12 
cells, with similar effects from GLS1 inhibition by 10 µM BPTES in cells supplied with 
Gln containing WM.  B. iO2 profiles in uncoupled MEF cells which show a different 
respiratory response compared with the HCT116 and PC12 cells.  C.  MEF cells are 
able to produce a respiratory response in the absence of Gln, making them is less 
sensitive to glutaminolysis inhibition.   
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3.3.3 Differential contribution of key metabolic substrates and O2 in 
HIF signalling 
 
Metabolic substrates play important roles in cancer cells during hypoxia.  High 
levels of glycolysis and glutaminolysis are important for cell survival.  Gln and Glc 
are important in HIF-signalling during hypoxia, which has been shown by 
deprivation of one or both of these substrates leading to inhibition of HIF-1α 
accumulation under hypoxic conditions (Kwon and Lee, 2005).  It has also been 
demonstrated that under O2 and Glc deprivation down-regulation of HIF signalling 
can occur via disruption of translational processes as a result of cellular ATP 
depletion (Zhdanov et al., 2013).  Using differentiated PC12 cells the different 
factors which are involved in HIFα accumulation including; the availability of key 
metabolic substrates, OCR, iO2, hypoxic stress, activation of AMPK, Akt and Erk, 
cellular ATP levels and transcription of HIF-α and PHD were studied.   
Self-deoxygenation profiles for PC12 cells exposed to different WM for 2 hours 
under normoxic conditions at 37oC were done, the WM was replaced and 
intracellular O2 was then monitored at 4% O2.  Cells supplemented with Glc/Gln/Pyr 
showed the deepest and most rapid deoxygenation monitored over 5 hours, 
reaching 10 µM within 1 hour (Fig. 3.10A).  Gal/Gln and Gln treated cells took 75-90 
min, Glc/Gln/Pyr took 80-110 min and Glc/Gln cells took 130-160 min (Fig. 3.10A-C).  
Cells supplied with just Glc showed a much shallower curve and with no substrates 
showed very minor deoxygenation, similar to that seen in cells treated with 
antimycin A (AA), inhibiting respiration.  There is good correlation between OCR 
and initial cell deoxygenation (r=0.92, p<10-4).  OCR is highest in cells supplied with 
Gln with either Gal/Pyr or Pyr and lowest in cells with just Gal or no substrates (Fig. 
3.10C).   
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Figure 3.10.  Substrate composition dictates deoxygenation profiles upon 
exposure to 4% O2 in PC12 cells.   PC12 cells were seeded and differentiated for 
5 days (MitoXpress-Intra loading occurred 16 hours prior to the start of the pre-
incubation) and then pre-incubated with different metabolic substrates for 2 
hours.  Plates were then transferred to 4% O2 and measured. A-B.  iO2 levels in cells 
supplied with Glc (A) or Gal (B), data recorded at 4% O2, cells were transferred from 
20.9% O2 and monitored for changes in cell deoxygenation.  When mitochondrial 
respiration is inhibited with antimycin A (AA) iO2 levels remain close to ambient.  C.  
Initial cell deoxygenation rates calculated from slopes from (A) and (B) during the 
first 40 min.   
 
From these results as one might expect HIF-2α was rapidly stabilised in cells 
supplied with Gln with Gal/Pyr or Glc/Pyr.  Cells with Glc/Gln or Gal/Gln showed an 
increase in HIF-2α accumulation with maximum levels reached after 3 hours (Fig. 
3.11A).  Cells supplied with Gal were unable to stabilise HIF-2α under anoxic 
conditions without both Gln/Pyr (Fig. 3.11A-B).  Low respiring cells without Gln 
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showed very little HIF-2α stabilisation when exposed to 4% O2 for up to 4 hours.  A 
strong inverse correlation was observed between HIF-2α and iO2 over 2-4 hours (r=-
0.57- -0.68, p<10-3).  A large decrease in ATP was seen in all cells deprived of Glc 
(Fig. 3.11B).   
Under anoxic conditions for 2 hours the pattern of HIF-2α stabilisation was very 
different (Fig. 3.11A-B).  Cells supplemented with Glc showed high protein levels of 
HIF-2α, correlating nicely with ATP levels (r=0.89, p<10-5) cells with Gal/Pyr/Gln and 
Pyr/Gln showed moderate levels, which were much lower than the levels seen at 
4% and small amounts of HIF-2α were observed in Gal/Gln cells.  Cells supplied with 
Gal/Pyr showed hardly any HIF-2α in any condition (Fig. 3.11A).  There was a 
dramatic increase in HIF-2α stabilisation in cells supplied with Glc/Pyr under anoxic 
conditions compared to the minimal stabilisation seen under hypoxia.   
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Figure 3.11.  Substrate composition dictates HIF-2α stabilisation in PC12 
cells exposed to different O2 conditions.   PC12 cells were incubated with 
different metabolic substrates for 2 hours and then maintained at 21% O2 or 
moved to 4% for 2-4 hours or 0% O2 for 2 hours, proteins were then isolated.   A. 
Western blot of HIF-2α in cells exposed to different WM at 4% O2 for 2-4 hours or 
0% for 2 hours.  B.  Results of quantitative analysis of HIF-2α levels plotted, along 
with corresponding ATP levels which were measured in PC12 after 2 hours pre-
incubation with different metabolic substrates and 0-4 hours exposure to 4% O2 
using the CellTiter-Glo assay, n = 4.   
 
The effect of GLS1 inhibition with BPTES on respiration was studied under hypoxia, 
an increase in iO2 was observed in cells supplied with Gln at 4% O2 showing a 
reduction in the respiration rate (Fig. 3.12A).  Significant reductions in ATP levels in 
cells with Gln at 4% O2 treated with BPTES were witnessed compared to non-
 
 
94 
 
treated (Fig. 3.12B).  The reductions were only seen in cells supplemented with Gln, 
demonstrating the specificity of BPTES.   
ATP levels under normoxia (19-21% O2) were similar in different WM.  However, 
after 4 hours exposure to 4% O2 cells supplied in Gal/Gln/Pyr had significantly lower 
ATP levels compared to Glc control (p<0.01), which was lower still when Pyr was 
excluded in cells fed on Gal/Gln (Fig. 3.12B).  The effect was greater still when cells 
were placed under anoxic conditions for 2 hours (Fig.3.12B).   
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Figure 3.12.  Inhibition of GLS1 changes respiratory response in cells 
supplied with Gln containing WM at 4% O2.  PC12 cells were seeded and 
differentiated for 5 days (MitoXpress-Intra loading occurred 16 hours prior to the 
start of the pre-incubation) and then pre-incubated with different metabolic 
substrates for 2 hours.  Inhibition of GLS1 with 10 µM BPTES occurred 1 hour 
prior to the start of the measurement.  Plates were then transferred to 4% O2 and 
measured.  A. iO2 profiles for (Glc/Pyr/Gln and Gal/Pyr), (Gln Glc/Pyr and Gal/Gln) 
and (Glc/Gln and Glc) with and without 10 µM BPTES treatment at 4% O2.  
Reduction in respiration with Increases in iO2 was observed in cells inhibited with 
GLS1 and supplied with Gln.  B.  ATP levels in cells supplied with Glc, Gal/Gln/Pyr 
and Gal/Gln at 19-21%, 4% and 0% treated with either 10 µM BPTES or mock DMSO.   
Data are shown as mean with standard deviation.  * show statistical significance 
between control cells (supplied with Glc and not treated with BPTES) (p<0.01), ** 
shows significance in ATP between BPTES (+) and BPTES (-) cells (p<0.01) n=3, all 
other results were not statistically significant. 
 
** 
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Phosphorylated Akt data reveal an increase in all samples under hypoxic conditions 
compared to normoxic samples.  p-AMPK (Thr172) and p-mTOR (Ser2448) showed 
similar levels in all O2 conditions in cells in Glc/Gln/Pyr WM.  Proteins involved in 
HIF-activation, p-Akt (Thr308 and Ser473) and p44/42 Erk1/2 (Thr202/Tyr204) 
showed a substantial increase in protein levels after 2 H at 4 % O2, which decreased 
after 4 hours at 4% O2 and was only very slightly increased under anoxic conditions 
for 2 hours.  When grown with Glc/Gln/Pyr HIF-1/2α levels rose with increasing 
exposure to 4% O2, however decreased levels were witnessed under anoxic 
conditions.  In cells supplied with Gal/Gln/Pyr increased HIF-1/2α protein levels 
were observed after 2 hours, which decreased significantly upon treatment with 
BPTES.  In cells supplied with Glc/Pyr a substantial decrease in HIF-1/2α protein 
levels was seen at 4% O2, with HIF-1/2α protein levels only found under anoxic 
conditions.    
AMPK phosphorylation (Thr308) remained relatively steady in cells supplied to 
Glc/Gln/Pyr in various O2 conditions.  However when the medium was switched to 
Gal/Gln/Pyr and the cells exposed to O% O2 a considerable increase in 
phosphorylation was observed in control and BPTES treated cells.  Differences in 
Akt phosphorylation (Thr308 and Ser 473), were also observed in Gal/Gln/Pyr WM 
with phosphorylation levels sustained at 4% O2 for at least 4 hours whereas at 
Glc/Gln/Pyr levels decreased under these conditions.  With GLS inhibition these Akt 
phosphorylation levels increased in cells supplied with Gal/Gln/Pyr, an effect not 
seen in Glc/Gln/Pyr supplied cells.  A similar phenomenon was seen for p44 and p42 
Erk phosphorylation which increased under hypoxia along with BPTES treatment 
(Fig. 3.13).   
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Figure 3.13.  Effects of metabolic substrates on the levels of HIF-α and the 
phosphorylation of HIF-regulating proteins.  A.   Western blotting analysis of 
HIF-1/2α and protein phosphorylation levels in WM containing Glc/Gln/Pyr (A.) and 
WMs without Glc (B.) or Gln (C.)  GLS1 activity was inhibited with 10 µM BPTES 
(DMSO was used as mock control). D.  Analysis of the effects of Glc (green) and Gln 
(blue) depletion on HIF-2α levels; bands are highlighted in corresponding colours in 
B and C. Data are normalised to the corresponding values in Glc/Gln/Pyr medium at 
19% O2 (1 a.u.). E.   Analysis of the effects of GLS1 inhibition on HIF-2α levels in WM 
containing Gal/Gln/Pyr (red in B). Data are normalised to the corresponding values 
in cells treated with mock at 19% O2 (1 a.u.). Qualitative data corrected to total 
protein levels shown in supplemental 2A-C.  * - show significant difference (p < 0.05) 
from corresponding values: in Glc/Gln/Pyr medium (D); without BPTES (E). 
* * * 
* 
* * 
* * 
* 
* 
* * 
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Immunofluorescence shows the effects of Glc and Gln on nuclear HIF-1 
accumulation at different O2 levels.  Analysis revealed similar levels of HIF-1α in 
cells supplied with Glc/Gln/Pyr and Gal/Gln/Pyr and grown under 4 % O2, however 
in cells with Glc/Pyr WM HIF-1α levels were only observed under anoxic conditions.  
Nuclear HIF-1α levels were higher in cells supplied with Glc/Pyr compared with 
Glc/Gln/Pyr cells under O% O2.  Treatment with BPTES caused a decrease in HIF-1α 
levels in Glc/Gln/Pyr cells, though the drop was much more dramatic in Gal/Gln/Pyr 
treated cells (Fig. 3.14a-B).   
 
 Figure 3.14.  Effects of metabolic substrates on the levels of HIF-α and the 
phosphorylation of HIF-regulating proteins.  A.  Immunofluorescence images 
and of the most prominent effects of Glc and Gln on nuclear HIF-1α accumulation 
(Novus HIF-1α primary antibody (50 minutes) and Alexa-488 fluorescent secondary 
antibody (50 minutes)) at different O2 availability. Cells were incubated for 4 hours 
at 4% O2 or 2 hours at 0%. DAPI was used for nuclear counterstaining. B. 
Quantitative analysis of HIF-1α accumulation from analysing 5–20 cells in 3 
independent experiments.   Error bars represent SD. * - show significant differences 
under normoxia in Glc/Gln/Pyr medium. Bar in A is 20 µM.   
 
The levels of AMPKα and Akt phosphorylation were assessed under conditions of 
oxygen/glucose deprivation (OGD).  Protein levels of HIF-2α were significantly 
higher in Glc/Gln compared with Gal/Gln supplied cells under hypoxic conditions.  
We found that AMPK phosphorylation was significantly higher in Gal/Gln supplied 
cells exposed to anoxia compared with Glc/Gln cells (Fig. 3.15 C, D).  Akt 
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phosphorylation was substantially higher in Glc/Gln WM compared to Gal/Gln after 
2 hours at 4 % O2, decreasing to similar levels after 4 hours at 4 % O2.  P-Erk 1/2 
protein levels were significantly higher in Gal/Gln WM compared to Glc/Gln.  Under 
anoxic conditions a large increase in p-AMPKα levels was observed in all WM 
without Glc, conversely, p-Akt levels decrease (Fig. 3.15 C, D).   
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Figure 3.15.   AMPKα and Akt phosphorylation and effect of AMPK inhibition 
on cell viability upon OGD.  PC12 cells were incubated with different metabolic 
substrates for 2 hours and then maintained at 19% O2 or moved to 4% or 0% O2 
for differing time points, proteins were then isolated.   A.  Western blotting 
analysis of HIF-2α and phosphorylation of HIF-regulating proteins in Glc/Gln or 
Gal/Gln media at different atmospheric O2.  B.  Quantitative analysis of A 
normalised to corresponding values in normoxic cells supplied with Glc/Gln. In 
WM containing Gal/Gln at 4% O2, Akt/Erk phosphorylation is increased; however 
HIF-2α levels are significantly lower, strong increase in p-AMPKα and decrease in 
p-Akt are highlighted by quadrangles. C.  Western blotting analysis shows a large 
increase in p-AMPKα levels under anoxia in all WM without Glc.  D.  Conversely, p-
Akt levels decrease.  In A, B and D, n = 3; in C, n = 4.  Phosphorylated proteins are 
corrected by total proteins shown in supplemental 2A-D.  Error bars represent SD. 
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3.4 DISCUSSION 
Glycolysis and OxPhos are the two main ATP generating pathways in mammalian 
cells. When Glc is absent, increases in OxPhos generated ATP enables the cell to 
survive (Marroquin et al., 2007).  We found in the presence of Gln and Pyr cells are 
able to survive without Glc, increasing OXPHOS flux and mitochondrial respiration 
(Fig. 3.3C and 3.4B-C).  These cells had the highest OCR, which was decreased with 
the addition of Glc as glycolysis was still able to produce ATP (Fig. 3.3A, Fig. 3.5A).   
During uncoupling, upon FCCP addition the ΔΨm is dissipated, mitochondrial Ca
2+ 
levels decrease, cytosolic pH increases and OxPhos is no longer able to produce 
ATP.  In fact ATP synthase works in reverse mode, utilising ATP in order to attempt 
to restore the ΔΨm, observed in many different physiological conditions such as 
cancer and ischemia (Ivanes et al., 2014, Pasto et al., 2014).  A deep and sustained 
deoxygenation was observed in cells supplied with Gln with Glc or Pyr when 
uncoupled with FCCP, demonstrating cancer cells glutaminolytic nature (Fig. 3.3C).  
Surprisingly, even without Glc uncoupled cells supplied with Gln/Pyr were able to 
produce this response.   
The reasoning behind the deep and sustained deoxygenation in cells supplied with 
Gln in combination with Glc or Pyr was investigated studying multiple factors 
including ATP, ΔΨp, ΔΨm, mitochondrial Ca2+ levels, extracellular acidification, key 
metabolic proteins, metabolic substrate entry into the cell and mitochondria and 
glutaminolysis.  ATP was not the limiting factor to the deoxygenation response to 
FCCP observed, ATP levels were only sustained in those cells supplied with Glc upon 
uncoupling (Fig. 3.5B).  The respiratory response to FCCP did not correlate with ATP 
levels, which dropped rapidly upon uncoupling in the absence of Glc, indicating that 
mitochondrial respiration does not depend on ATP levels (Fig. 3.5A-B).  Even cells 
supplied with Gal/Gln/Pyr or Gln/Pyr were able to produce a substantial respiratory 
response to FCCP which lasted for at least 1 hour (Fig. 3.3C).   
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Although the mitochondrial membrane potential was similar in all cases, a strong 
increase in respiration was seen only in the cells fed on Gln combined with either 
Glc or Pyr (Fig. 3.3C, Fig. 3.6A-B).  Gln transport into the cell and mitochondria was 
investigated to see why Gln needed to be combined with either Pyr or Glc for this 
response to uncoupling.  Gln is transported into the cell via the Gln transporter SN1 
and the amino acid transporters ASCT1/ASCT2 (Fig. 3.16)  (Bode, 2001).  These all 
involve Na2+ co-transport, which could be affected by ΔΨp depolarisation.  However 
depolarisation of the ΔΨp was not observed making it likely plasma membrane Gln 
transport would be unaffected.  Gln is transported into the mitochondria via the 
mitochondrial Gln carrier which is dependent on ∆pH, causing FCCP to suppress this 
transport (Albrecht et al., 2000).  However cytosolic Gln can be converted into 
glutamate (Glu) which can be transported into the mitochondria via the Glu 
transporter or the Glu-Aspartate (Asp) antiporter in the malate-asp shuttle (Fig. 
3.17).  Transport via the Glu-Asp antiporter requires NADH; meaning cells without 
Glc or Pyr would not be able to transport Gln into the mitochondria this way.  
However this antiporter is electrogenic, requiring an electrochemical potential 
across the mitochondrial membrane, which is dissipated upon uncoupling (LaNoue 
and Tischler, 1974).  After FCCP addition transport of Gln is no longer achieved by 
the Glu-Asp antiporter, and either Glc or Pyr are necessary for the mitochondrial 
Gln transporter to be functional and Gln to enter the mitochondria (Fig. 3.16).   
Glc enters the via through Glc transporters GLUT1 and GLUT4, Glc is then converted 
into Pyr, which is able to enter through the H+-linked monocarboxylate transporter 
(MCT).  Pyr is co-transported with H+ into the mitochondria through the 
mitochondrial pyruvate carrier (MPC) where it is converted into acetyl-CoA and 
then eventually α-ketoglutarate (α-KG) (Bricker et al., 2012).  As Pyr transport is H+-
coupled, the rate will decrease upon uncoupling (Herzig et al., 2012).  This explains 
the lack of respiratory increase in FCCP treated cells supplied with Glc, Pyr or 
Glc/Pyr (Fig. 3.3B-C).   
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Figure 3.16.  Transport of metabolic substrates across the plasma membrane. Gln 
is transported into the cell via the glutamine transporter SN1, or the amino acid 
transporter ASCT1 or ASCT2, all of which involved Na+ co-transportation.  Pyr enters 
the cell via a proton linked monocarboxylate transporter (MCT).  Glc enters the cells 
via the Glc transporters GLUT-1 and GLUT-4 and is utilised in the glycolytic pathway 
to produce Pyr.   
 
It is of importance that in the presence of Gln, α-KG transport can activate Glc 
transport into the cells.  Α-KG acts by causing transcriptional repression of the 
glucose sensitive thioredoxin-interacting protein (TXNIP), which is normally induced 
is response to high levels of Glc, providing a negative feedback loop (Fig. 3.17).  Α-
KG acts via the activation of the transcriptional factor MondoA protein (Stoltzman 
et al., 2011, Han and Ayer, 2013).  In the absence of Gln, α-KG levels are decreased, 
decreasing Glc uptake via the formation of MondoA:MIX (Max-like protein X) 
complex which causes MondaA to activate TXNIP expression (Fig. 3.17).  Therefore 
in the presence of Gln, Glc fuelled TXNIP induction is repressed and Glc transport 
increased (Fig. 3.13) (Stoltzman et al., 2011, Han and Ayer, 2013).   
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Figure 3.17.  Transport of metabolic substrates across the mitochondrial 
membrane.   Gln is transported into the mitochondria via a Gln/H+ antiporter, or is 
converted into glutamate (Gln) and enters by the malate-aspartate (Asp) shuttle 
and is transformed into α-ketoglutarate (α-KG).  Pyr is transported by the 
mitochondrial pyr carrier (MPC).  1 µM FCCP depolarises ∆Ψm and dissipates ∆pH, 
decreasing Gln and Gln mitochondrial entry.  Thioredoxin (TXN) plays an important 
role in protecting the cell against oxidative stress.  TXN-interacting protein (TXNIP) 
down regulates the expression and activity of TXN which can be transcriptionally 
activated by Monda A, inhibiting Glc uptake.  Glutaminolytically derived α-KG 
causes transcriptional repression of TXNIP via activation of MondoA:Mix 
(MondoA:Max-like protein X) which inhibits TXNIP and therefore prevents TXNIP 
GLUT inhibition.   
 
It should also be noted that FCCP causes a decrease in mitochondrial Ca2+ levels 
(Fig. 3.7 B), which are known to regulate the mitochondrial enzymes pyruvate 
dehydrogenase (PDH), isocitrate dehydrogenase (IDH) and α-KG dehydrogenase (α-
KGDH) (Denton, 2009).  Decreased activity of PDH and IDH as a result of FCCP 
treatment can lead to a reduction of α-KG formed.  It would also mean less 
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reducing equivalents are formed which would have an impact on ATP and ROS 
production.  Increased levels of ROS would be of particular concern to cells in WM 
without Gln, one of the precursors for the antioxidant glutathione (Roth et al., 
2002)   It has been shown that glutathione and superoxide dismutase are reduced 
after FCCP treatment, along with an increase in ROS after 48 hours (Han and Park, 
2011).   
As expected, glycolytic activity was inversely related to OCR, demonstrated by 
Glc/Pyr and Glc which had the lowest basal OCR of those cells supplied with Glc, 
also had the highest basal L-ECA values (Fig. 3.3A, Fig. 3.5C).  The most significant 
increase in L-ECA upon uncoupling was observed in cells supplied with Glc/Gln, 
possibly as a result of the repression of TXNIP by α-KG increasing Glc uptake (Fig. 
3.5C, Fig. 3.15) (Stoltzman et al., 2011, Han and Ayer, 2013).    
It is known that cancer cells are highly glutaminolytic, inhibition of glutaminolysis 
with BPTES decreased the respiratory response to FCCP in both PC12 and HCT116 
cells (Fig. 3.8A-C and 3.9A-C).  Glycolytic activity was increased in response to GLS1 
inhibition in cells supplied with Glc/Gln with or without Pyr (Fig. 3.8D).  However, in 
MEFs a different pattern of substrate dependent responses to uncoupling was 
observed (Fig. 3.9B-C).  Glc and Pyr had a larger role to play in the respiratory 
response in these cells compared to PC12 and HCT116 cells, indicating a reduced 
role of glutaminolysis which was highlighted by the smaller decrease in response to 
uncoupling as a result of GLS1 inhibition (Fig. 3.9B).    
A reduction in the phosphorylation of Erk p44/p42 (Thr202/Tyr204), Akt (Ser473), 
AMPKα (Thr173) and mTOR (Ser2448) after FCCP addition in cells supplied with Glc 
with Gln or Pyr was observed (Fig. 3.7D).  The reduction in Erk and Akt 
phosphorylation was more marked in cells supplied with Glc/Gln/Pyr or Glc/Gln, the 
cells which demonstrated the strong respiratory response to FCCP.  This effect may 
be as a result of an increased NAD/NADH ratio together with Ca2+ affecting the 
phosphorylation of these proteins.  The increase in AMPKα phosphorylation in cells 
supplied with Glc was surprising as ATP levels were not significantly altered in these 
cells with FCCP addition (Fig. 3.7D).  AMPK can be activated by increased ROS levels 
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as well as an increase AMP/ATP ratio, it is possible that a reduction in ROS levels is 
sufficient to decrease AMPK phosphorylation (Dugan et al., 2013, Hardie et al., 
2012).  In the absence of Glc, in cells fed with Gal/Gln a dramatic decrease in p-
AMPK levels was observed, which can be explained by induction of apoptosis 
shown by a very substantial decrease in PARP levels (Fig. 3.3D).   
Next, the factors involved in HIF-α accumulation were studied including the 
availability of key metabolic substrates, OCR, iO2, hypoxic stress, activation of 
AMPK, Akt and Erk, cellular ATP levels and transcription of HIF-α and PHD.  Cellular 
HIF-1/2α levels can increase dependent on level and duration of hypoxia or 
metabolic deprivation.  HIF pathways are important in metabolic regulation, giving 
them a pivotal role under hypoxia or metabolic substrate deprivation.  Levels of iO2 
and metabolic substrates are also able to modulate these pathways. Gln was the 
one of the main contributors to HIF-2α stabilisation at 4% O2, as it dictates the 
levels of cell deoxygenation, which was demonstrated in cells without Gln which 
were unable to stabilise HIF when transferred from 19 % to 4 % O2 (Fig. 3.11A-B).  
For HIF to be stabilised O2 levels need to decrease below 40 mmHg (50 µM) which 
did not occur without Gln, however in the presence of Gln O2 levels went under 10 
µM (Fig. 3.10A-B) (Semenza, 2012).  Cells supplied with Gal/Gln/Pyr were 
deoxygenated to below 10 µM and remained at that level for the first 2 hours of 
hypoxic exposure, allowing HIF accumulation to occur (Fig. 3.10B and 3.11A).  
Whereas cells supplied with Glc/Pyr showed lower cell deoxygenation and lower 
levels of HIF accumulation.  However, cells supplied with Glc/Gln showed high levels 
of cell deoxygenation but lower levels if HIF-2α which suggests that substrate 
dependent effects other than cellular O2 play a role in HIF accumulation under 
hypoxia (Fig. 3.10A, Fig. 3.11A).   
Glutaminolysis was shown to be important for respiratory responses at 4 % O2 as 
well as during FCCP treatment (Fig. 3.12A).  Without Gln or with BPTES treatment 
inhibiting GLS1 causing cellular α-KG levels to decrease which may lead to a 
decrease in PHD activity, increased HIF stabilisation occurs under these conditions 
(Seltzer et al., 2010).  However, this phenomenon was not observed in BPTES 
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treated cells supplied with Glc/Gln/Pyr or Glc/Pyr (Fig. 3.13A, B).  In these cells 
intracellular O2 levels are sufficient for PHD hydroxylation (Fig. 3.12A).  It has been 
shown that Pyr can activate HIF via interactions with the α-KG binding site on PHDs 
(Lu et al., 2005); this may clarify why we saw higher HIF-α levels in Glc/Gln(Fig. 
3.11A), which generate Pyr via glycolysis, supplied cells compared with Gal/Gln.   
Substrate availability can determine the rate of HIF-α synthesis (Fig. 3.11A-B).  This 
is likely to be from differences in ATP levels and HIF translation pathways (Fig. 3.11B 
and 3.13A-D).  In hypoxia a large variability in cell bioenergetics and local 
oxygenation was observed, which was dependent on substrate composition. It is 
known that glucose is required for increased glycolytic flux necessary for cell 
survival under hypoxic conditions (Callahan et al., 1990).  In the cells deprived of 
Glc, ATP continuously decreased at 4% O2 and dropped dramatically at 0% 02 (Fig. 
3.11B).  Under anoxic conditions the main driver for HIF accumulation was ATP 
availability (Fig. 3.11B).  Investigation of the effect of OGD on AMPKα and Akt 
phosphorylation revealed that an increase in p-AMPK levels in PC12 cells is 
associated with reduced production of HIF-α upon OGD, whereas Akt/Erk 
phosphorylation and O2-dependent accumulation of HIF-α are not tightly linked.  
Differential regulation of the respiratory response to FCCP by metabolic 
environment suggests that mitochondrial uncoupling has a potential for substrate-
specific inhibition of cell function, and can be explored for selective cancer 
treatment. These results also show that both supply and utilisation of key metabolic 
substrates (Glc, Gln and Pyr) can affect the pattern of HIF-1/2α accumulation by 
differentially regulating iO2 and ATP levels and Akt/Erk/AMPK pathways.  Inhibition 
of key metabolic pathways (e.g. glutaminolysis) can modulate HIF regulatory 
pathways, metabolic responses and survival of cancer cells in hypoxia.  This data is 
of relevance to those studying neuronal and cancer metabolism under hypoxia.  
These studies can relate to a number of different physiological conditions such as, 
deprivation of nutrients and O2 as a result of ischemia/stroke, diabetes mellitus, 
liver carcinoma and cancer associated changes in uncoupling protein expression 
levels (Kalogeris et al., 2014, Heller and Chow, 2014, El-Serag et al., 2008).   
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3.5 CONCLUSIONS 
To conclude these results demonstrate that the CEB platform is able to distinguish 
between the contributions of the main metabolic pathways; OXPHOS, Krebs cycle 
and glycolysis to ATP production and can be used to investigate toxicities from 
exogenous compounds, offering a more in-depth and more sensitive analysis 
compared to existing toxicity testing methods.  The CEB platform can also be used 
to distinguish differences in bioenergetics between both cells and treatments, 
making it a valuable research technique.  It can also be used to perform in-depth 
metabolic studies.    
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OVERALL CONCLUSIONS 
 
In this project it has been demonstrated that the CEB platform is a very useful tool 
for bioenergetics research and mechanistic studies of cell metabolism can be used 
to delineate the contributions of the main metabolic energy generating pathways.  
This system allows comprehensive assessment of mitochondrial toxicity, offering a 
more selective and sensitive analysis compared to conventional toxicity assays such 
as MTT, ATP, cell viability.  But it has shown it can also be used to differentiate 
metabolic variances in ATP production between cell lines and/or treatments.   
Using the CEB platform an in-depth study was performed, which showed that 
metabolic substrates are able to dictate that respiratory response to energy stress 
(FCCP uncoupling), and that mitochondrial uncoupling has a potential for substrate-
specific inhibition of cell function.  This approach and analytical methodology is 
applicable to a number of different cell models and research areas such as 
deprivation of nutrients and O2 as a result of ischemia/stroke, diabetes mellitus and 
cancer associated changes in uncoupling protein expression levels. Differential 
regulation of the respiratory response to FCCP by metabolic environment suggests 
that mitochondrial uncoupling has a potential for substrate-specific inhibition of cell 
function, and can be explored for selective cancer treatment.  
The results indicate that both supply and utilisation of key metabolic substrates 
(Glc, Gln and Pyr) can affect the pattern of HIF-1/2α accumulation by differentially 
regulations iO2 and ATP levels and Akt/Erk/AMPK pathways.  Inhibition of key 
metabolic pathways (e.g. glutaminolysis) can modulate HIF regulatory pathways, 
metabolic responses and survival of cancer cells in hypoxia.  This data is of 
relevance to those studying neuronal and cancer metabolism under hypoxia.  
However it can be applied to many (patho)physiological diseases such as reduced 
nutrient supply and O2 during ischemia/stroke, hypoglycaemia in diabetes mellitus 
patients and liver carcinoma (Kalogeris et al., 2014, Heller and Chow, 2014, El-Serag 
et al., 2008).   
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The last study revealed a new regulatory pathway for PDH E1-α phosphorylation.  It 
has been shown that phosphorylation of PDH E1-α can occur in a manner 
independent of the HIF-1/PDK1 axis, mitochondrial respiration and the demand for 
acetyl-CoA in the Krebs cycle.  These findings are of particular importance to those 
who are investigating the use of PDK1 inhibitors as possible treatments for patients 
with diabetes, heart disease or cancer.   
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FUTURE WORK 
To complete this work further experiments are required.  Firstly PDH activity needs to be 
measured to check that there is not a increased in PDH E1α phosphorylation to 
compensate for increase PDH activity in these cells under hypoxic conditions, however this 
is unlikely.  PDH activity can be tested using kit such as the one sold by Abcam.  A definitive 
reason for the increased phosphorylation of PDH in SCO2-/- under normoxia needs to be 
investigated.  PDH levels should be studied in a larger range of O2 concentrations to find 
when PDH becomes phosphorylated or if it is a gradual effect.  A possible reasoning for the 
change in PDH phosphorylation status in the SCO2-/- cells is connected with the hypothesis 
that SCO2-/- cells undergo reductive carboxylation under hypoxic conditions.  If this were 
the case glycolytically derived acetyl-CoA would not be needed as it would be generated 
through reverse Krebs cycle from α-KG formed through glutaminolysis.  This would explain 
why these cells are unable to survive when glutaminolysis is inhibited as the reductive 
carboxylation is unable to form necessary lipids required for growth. This can be tested 
using carbon labelling techniques combined with mass spectrometry.  
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APPENDIX 
 
 
Supplemental 1. MTT test performed on both HaCaT and HT1080 cells, showing 
good levels of biocompatibility after 24 hours exposure to various MIP NP 
conditions.  Data obtained from Francesco Canforotta in Leicester University, UK.   
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Supplemental 2. Western Blotting analysis of total mTOR, Akt, Erk1/2 and AMPK 
protein levels.  PC12 cells were incubated in different metabolic substrates for 2 
hours and then retained at 21% O2 or transferred to 4% or 0% O2 for the shown 
number of hours.  The data are complementary to the analysis of phosphorylated 
protein levels shown in Fig. 3.13A-E and Fig. 3.15A-D.   
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